Dsrna molecule for regulating expression of agt

By using dsRNA or siRNA to target the AGT gene, effective regulation of angiotensin expression is achieved, and the problem of difficulty in treating hypertension in the prior art is solved, which significantly reduces blood pressure levels.

WO2025007961A1PCT designated stage expired Publication Date: 2025-01-09RONA BIOSCIENCE LTD +1
View PDF 16 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2024/103907
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-07-06
Filing Date
2024-07-05
Publication Date
2025-01-09

AI Technical Summary

Technical Problem

The prior art is difficult to effectively regulate the expression of angiotensin (AGT), making it difficult to treat related diseases such as hypertension.

Method used

Double-stranded RNA (dsRNA), especially small interfering RNA (siRNA), is designed to inhibit the specific double-stranded nucleotide sequence of the AGT gene, and silencing it by targeting AGT mRNA, thereby reducing its expression.

Benefits of technology

Effectively lowering the expression of angiotensin and significantly lowering blood pressure, providing a new method for treating hypertension and related diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PCTCN2024103907-FTAPPB-I100001
    Figure PCTCN2024103907-FTAPPB-I100001
  • Figure PCTCN2024103907-FTAPPB-I100002
    Figure PCTCN2024103907-FTAPPB-I100002
  • Figure PCTCN2024103907-FTAPPB-I100003
    Figure PCTCN2024103907-FTAPPB-I100003
Patent Text Reader

Abstract

Provided are a double-stranded RNA for inhibiting the expression of angiotensinogen (AGT) in cells; a vector and cell comprising an encoding nucleotide thereof; and a method for using the dsRNA, vector or cell to treat a disease or symptom mediated by or associated with the expression of AGT in a subject.
Need to check novelty before this filing date? Find Prior Art

Description

dsRNA molecules that regulate AGT expression Technical Field

[0001] The present invention relates to the field of RNA interference. Background Art

[0002] Angiotensinogen (AGT), an alpha-globulin, is located upstream of the renin-angiotensin-aldosterone system (RAAS) in blood pressure regulation and is the sole precursor of all angiotensin peptides. Inactive AGT is sequentially cleaved by renin and angiotensin-converting enzyme (ACE) into active angiotensin II (Ang-II). Ang-II exerts its effects by binding to its receptors (AT1–4).

[0003] Angiotensinogen is primarily synthesized and secreted by the liver and is present in the α-globulin fraction of plasma. Furthermore, angiotensinogen is present in various tissues that express the local RAAS. Elevated angiotensinogen levels are associated with essential hypertension. Transgenic mice expressing the rat angiotensinogen gene exhibit hypertension, while mice lacking the angiotensinogen gene exhibit hypotension.

[0004] Regulation of AGT production is multifactorial and occurs at both the transcriptional and posttranscriptional levels. Ang II itself, glucocorticoids, estrogens, thyroxine, growth hormone, and various cytokines influence AGT production. Physiological and pathological conditions, such as pregnancy, oral contraceptive use, increased glucocorticoid secretion (due to hyperadrenalism or chronic stress), and chronic inflammation can lead to increased AGT production. Conversely, deficiencies of the pituitary, thyroid, gonads, or adrenal glands are associated with low plasma AGT levels.

[0005] The primary source of circulating AGT is hepatocytes, which secrete it constitutively, resulting in relatively stable plasma levels regardless of acute stress or cardiovascular changes. In addition to the liver, adipocytes and epithelial cells of the renal proximal tubules, as well as the brain, also express Agt, where production contributes to local Ras activation. In the brain, AGT is primarily expressed in astrocytes (Milsted et al., 1990), while AT1 is present in brain endothelial cells (Wosik et al., 2007). Interestingly, mice lacking AGT display blood-brain barrier disruption and disorganized occlusion at tight junctions (Wosik et al., 2007), strongly suggesting that astrocytes maintain blood-brain barrier properties through the AGT-Ang-II-AT1 pathway. Furthermore, evidence of a positive correlation between BMI and circulating AGT levels suggests that AGT production in adipocytes contributes to circulating AGT levels.

[0006] AGT was the first gene discovered to be associated with essential hypertension. Human genetic evidence and animal studies suggest that blocking or inhibiting AGT expression can significantly lower blood pressure. One approach to treating hypertension is to reduce AGT expression through RNA interference (RNAi) using small interfering RNA (siRNA).

[0007] There is a need in the art for compositions and methods for treating diseases, disorders, and conditions associated with angiotensinogen.

[0008] Reduction of AGT expression by double-stranded RNA (dsRNA), particularly small interfering RNA (siRNA), based on the RNA interference mechanism is a novel approach for treating diseases, disorders and conditions associated with angiotensinogen.

[0009] Summary of the Invention

[0010] The present invention provides novel double-stranded RNA (dsRNA), vectors, cells, and pharmaceutical compositions and kits comprising the dsRNA, vectors, or cells for inhibiting the expression of angiotensinogen (AGT) in cells, as well as methods for using the dsRNA, vectors, cells, pharmaceutical compositions, and kits to inhibit or reduce angiotensinogen (AGT) gene expression or to treat diseases or conditions that benefit from reduced angiotensinogen (AGT) expression.

[0011] In a first aspect, the present invention provides a double-stranded nucleic acid (dsRNA) for inhibiting the expression of angiotensinogen (AGT) in a cell, the dsRNA comprising a sense strand and an antisense strand forming a double-stranded region, wherein the sense strand and the antisense strand are each independently 15-30 nucleotides in length, and the antisense strand comprises a nucleotide sequence of at least 15 consecutive nucleotides of the nucleotide sequence shown in any one of SEQ ID NOs: 21-40.

[0012] In some embodiments, the sense strand comprises a nucleotide sequence of at least 15 consecutive nucleotides of the nucleotide sequence shown in any one of SEQ ID NOs: 1-20.

[0013] In some embodiments, the dsRNA is siRNA.

[0014] In some embodiments, the length of the double-stranded region is 15-25 nucleotide pairs, preferably 16-23 nucleotide pairs, and more preferably 18-20 nucleotide pairs.

[0015] In some embodiments, the antisense strand comprises a nucleotide sequence of at least 16 consecutive nucleotides, a nucleotide sequence of at least 17 consecutive nucleotides, a nucleotide sequence of at least 18 consecutive nucleotides, a nucleotide sequence of at least 19 consecutive nucleotides, or a nucleotide sequence of at least 20 consecutive nucleotides of the nucleotide sequence shown in any one of SEQ ID NOs: 21-40. In some preferred embodiments, the antisense strand comprises the nucleotide sequence shown in any one of SEQ ID NOs: 21-40.

[0016] In some embodiments, the sense strand comprises a nucleotide sequence of at least 16 consecutive nucleotides, a nucleotide sequence of at least 17 consecutive nucleotides, or a nucleotide sequence of at least 18 consecutive nucleotides of the nucleotide sequence shown in any one of SEQ ID NOs: 1-20. In some preferred embodiments, the sense strand comprises a nucleotide sequence shown in any one of SEQ ID NOs: 1-20.

[0017] In a preferred embodiment, the siRNA comprises any one of the following paired sense strand sequences and antisense strand sequences:

[0018] (1) Sense strand: SEQ ID NO: 1, antisense strand: SEQ ID NO: 21;

[0019] (2) Sense strand: SEQ ID NO: 2, antisense strand: SEQ ID NO: 22;

[0020] (3) Sense strand: SEQ ID NO: 3, antisense strand: SEQ ID NO: 23;

[0021] (4) Sense strand: SEQ ID NO: 4, antisense strand: SEQ ID NO: 24;

[0022] (5) Sense strand: SEQ ID NO: 5, antisense strand: SEQ ID NO: 25;

[0023] (6) Sense strand: SEQ ID NO: 6, antisense strand: SEQ ID NO: 26;

[0024] (7) Sense strand: SEQ ID NO: 7, antisense strand: SEQ ID NO: 27;

[0025] (8) Sense strand: SEQ ID NO: 8, antisense strand: SEQ ID NO: 28;

[0026] (9) Sense strand: SEQ ID NO: 9, antisense strand: SEQ ID NO: 29;

[0027] (10) Sense strand: SEQ ID NO: 10, antisense strand: SEQ ID NO: 30;

[0028] (11) Sense strand: SEQ ID NO: 11, antisense strand: SEQ ID NO: 31;

[0029] (12) Sense strand: SEQ ID NO: 12, antisense strand: SEQ ID NO: 32;

[0030] (13) Sense strand: SEQ ID NO: 13, antisense strand: SEQ ID NO: 33;

[0031] (14) Sense strand: SEQ ID NO: 14, antisense strand: SEQ ID NO: 34;

[0032] (15) Sense strand: SEQ ID NO: 15, antisense strand: SEQ ID NO: 35;

[0033] (16) Sense strand: SEQ ID NO: 16, antisense strand: SEQ ID NO: 36;

[0034] (17) Sense strand: SEQ ID NO: 17, antisense strand: SEQ ID NO: 37;

[0035] (18) Sense strand: SEQ ID NO: 18, antisense strand: SEQ ID NO: 38;

[0036] (19) sense strand: SEQ ID NO: 19, antisense strand: SEQ ID NO: 39; and

[0037] (20) Sense strand: SEQ ID NO: 20, antisense strand: SEQ ID NO: 40.

[0038] In some embodiments, substantially all of the nucleotides of the sense strand and substantially all of the nucleotides of the antisense strand are modified nucleotides. In other embodiments, all of the nucleotides of the sense strand and all of the nucleotides of the antisense strand are modified nucleotides.

[0039] In some embodiments, the sense strand and the antisense strand each independently comprise one or more nucleotide modifications selected from the group consisting of a 2'-O-methyl modification, a 2'-fluoro modification, an SCP modification, an ethylene glycol modification, and a modification of a phosphorothioate internucleotide linkage.

[0040] In some embodiments, the antisense strand is 21 nucleotides in length and has

[0041] (i) (counting from the 5' end) 2'-O-methyl modified nucleotides at positions 1, 3, 5, 9, 11, 13, 15, 17, 19 and 21, and 2'-fluoro modified nucleotides at positions 2, 4, 6, 8, 10, 12, 14, 16, 18 and 20; and / or

[0042] (ii) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, between nucleotide positions 2 and 3, between nucleotide positions 19 and 20, and between nucleotide positions 20 and 21 (counting from the 5' end).

[0043] In some embodiments, the antisense strand is 21 nucleotides in length and has

[0044] (i) (counting from the 5' end) 2'-O-methyl modified nucleotides at positions 1, 3, 5, 9, 11, 13, 15, 17, 19, 20 and 21, and 2'-fluoro modified nucleotides at positions 2, 4, 6, 8, 10, 12, 14, 16 and 18; and / or

[0045] (ii) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, between nucleotide positions 2 and 3, between nucleotide positions 19 and 20, and between nucleotide positions 20 and 21 (counting from the 5' end).

[0046] In some embodiments, the antisense strand is 21 nucleotides in length and has

[0047] (i) 2'-O-methyl modified nucleotides at positions 3, 4, 6, 8, 9, 10, 11, 13, 15, 16, 17, 18, 19, 20 and 21 (counting from the 5' end);

[0048] (ii) a 2'-fluoro-modified nucleotide at position 14 (counting from the 5' end);

[0049] (iii) 2′-deoxy modifications at positions 2, 5, 7, and 12 (counting from the 5′ end);

[0050] (iv) an SCP modification at position 1 (counting from the 5' end); and / or

[0051] (v) Phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, between nucleotide positions 2 and 3, between nucleotide positions 19 and 20, and between nucleotide positions 20 and 21 (counting from the 5' end).

[0052] In some embodiments, the antisense strand is 21 nucleotides in length and has

[0053] (i) 2'-O-methyl modified nucleotides at positions 3, 5, 9, 11, 13, 15, 17, 19, 20 and 21 (counting from the 5' end);

[0054] (ii) 2′-fluoro-modified nucleotides at positions 2, 4, 6, 8, 10, 12, 14, 16, and 18 (counting from the 5′ end);

[0055] (iii) GNA modification at position 7 (counting from the 5′ end);

[0056] (iv) an SCP modification at position 1 (counting from the 5' end); and / or

[0057] (v) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, between nucleotide positions 2 and 3, between nucleotide positions 19 and 20, and between nucleotide positions 20 and 21 (counting from the 5' end).

[0058] In some embodiments, the sense strand has a length of 19 nucleotides and has:

[0059] (i) 2'-O-methyl modified nucleotides at positions 1 to 6, 10 to 19 (counting from the 5' end), and 2'-fluoro modified nucleotides at positions 7-9; and / or

[0060] (ii) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, between nucleotide positions 2 and 3, and between nucleotide positions 18 and 19 (counting from the 5' end).

[0061] In some embodiments, the antisense strand comprises a sequence selected from any one of SEQ ID NOs: 81-105.

[0062] In some embodiments, the sense strand comprises a sequence selected from any one of SEQ ID NOs: 41-59.

[0063] In some preferred embodiments, the dsRNA comprises any one pair of sense strand sequence and antisense strand sequence selected from the group consisting of:

[0064] Sense strand: SEQ ID NO: 41, antisense strand: SEQ ID NO: 81;

[0065] Sense strand: SEQ ID NO: 42, antisense strand: SEQ ID NO: 82;

[0066] Sense strand: SEQ ID NO: 43, antisense strand: SEQ ID NO: 83;

[0067] Sense strand: SEQ ID NO: 44, antisense strand: SEQ ID NO: 84;

[0068] Sense strand: SEQ ID NO: 45, antisense strand: SEQ ID NO: 85;

[0069] Sense strand: SEQ ID NO: 46, antisense strand: SEQ ID NO: 86;

[0070] Sense strand: SEQ ID NO: 47, antisense strand: SEQ ID NO: 87;

[0071] Sense strand: SEQ ID NO: 48, antisense strand: SEQ ID NO: 88;

[0072] Sense strand: SEQ ID NO: 49, antisense strand: SEQ ID NO: 89;

[0073] Sense strand: SEQ ID NO: 50, antisense strand: SEQ ID NO: 90;

[0074] Sense strand: SEQ ID NO: 51, antisense strand: SEQ ID NO: 91;

[0075] Sense strand: SEQ ID NO: 52, antisense strand: SEQ ID NO: 92;

[0076] Sense strand: SEQ ID NO: 53, antisense strand: SEQ ID NO: 93;

[0077] Sense strand: SEQ ID NO: 54, antisense strand: SEQ ID NO: 94;

[0078] Sense strand: SEQ ID NO: 55, antisense strand: SEQ ID NO: 95;

[0079] Sense strand: SEQ ID NO: 56, antisense strand: SEQ ID NO: 96;

[0080] Sense strand: SEQ ID NO: 57, antisense strand: SEQ ID NO: 97;

[0081] Sense strand: SEQ ID NO: 58, antisense strand: SEQ ID NO: 98; and

[0082] Sense strand: SEQ ID NO: 59, antisense strand: SEQ ID NO: 99.

[0083] In some embodiments, the sense strand comprises a sequence selected from any one of SEQ ID NOs: 113-131.

[0084] In some embodiments, the dsRNA comprises any one pair of paired sense and antisense strand sequences selected from the group consisting of:

[0085] Sense strand: SEQ ID NO: 113, antisense strand: SEQ ID NO: 81;

[0086] Sense strand: SEQ ID NO: 114, antisense strand: SEQ ID NO: 82;

[0087] Sense strand: SEQ ID NO: 115, antisense strand: SEQ ID NO: 83;

[0088] Sense strand: SEQ ID NO: 116, antisense strand: SEQ ID NO: 84;

[0089] Sense strand: SEQ ID NO: 117, antisense strand: SEQ ID NO: 85;

[0090] Sense strand: SEQ ID NO: 118, antisense strand: SEQ ID NO: 86;

[0091] Sense strand: SEQ ID NO: 119, antisense strand: SEQ ID NO: 87;

[0092] Sense strand: SEQ ID NO: 120, antisense strand: SEQ ID NO: 88;

[0093] Sense strand: SEQ ID NO: 121, antisense strand: SEQ ID NO: 89;

[0094] Sense strand: SEQ ID NO: 122, antisense strand: SEQ ID NO: 90;

[0095] Sense strand: SEQ ID NO: 123, antisense strand: SEQ ID NO: 91;

[0096] Sense strand: SEQ ID NO: 124, antisense strand: SEQ ID NO: 92;

[0097] Sense strand: SEQ ID NO: 125, antisense strand: SEQ ID NO: 93;

[0098] Sense strand: SEQ ID NO: 126, antisense strand: SEQ ID NO: 94;

[0099] Sense strand: SEQ ID NO: 127, antisense strand: SEQ ID NO: 95;

[0100] Sense strand: SEQ ID NO: 128, antisense strand: SEQ ID NO: 96;

[0101] Sense strand: SEQ ID NO: 129, antisense strand: SEQ ID NO: 97;

[0102] Sense strand: SEQ ID NO: 130, antisense strand: SEQ ID NO: 98; and

[0103] Sense strand: SEQ ID NO: 131, antisense strand: SEQ ID NO: 99.

[0104] In some embodiments, the dsRNA is further conjugated to a ligand moiety comprising N-acetylgalactosamine, preferably at the 3' end of the sense strand.

[0105] In some embodiments, the ligand has the following structure:

[0106] in Indicates the position of linkage to the sense strand of the dsRNA via a phosphate group or a phosphorothioate group.

[0107] In some embodiments, the sense strand comprises a sequence selected from any one of SEQ ID NOs: 60-79.

[0108] In some preferred embodiments, the dsRNA comprises any pair of sense strand sequence and antisense strand sequence selected from the group consisting of:

[0109] Sense strand: SEQ ID NO: 60, antisense strand: SEQ ID NO: 81;

[0110] Sense strand: SEQ ID NO: 61, antisense strand: SEQ ID NO: 82;

[0111] Sense strand: SEQ ID NO: 62, antisense strand: SEQ ID NO: 83;

[0112] Sense strand: SEQ ID NO: 63, antisense strand: SEQ ID NO: 84;

[0113] Sense strand: SEQ ID NO: 64, antisense strand: SEQ ID NO: 85;

[0114] Sense strand: SEQ ID NO: 65, antisense strand: SEQ ID NO: 86;

[0115] Sense strand: SEQ ID NO: 66, antisense strand: SEQ ID NO: 87;

[0116] Sense strand: SEQ ID NO: 67, antisense strand: SEQ ID NO: 88;

[0117] Sense strand: SEQ ID NO: 68, antisense strand: SEQ ID NO: 89;

[0118] Sense strand: SEQ ID NO: 69, antisense strand: SEQ ID NO: 90;

[0119] Sense strand: SEQ ID NO: 70, antisense strand: SEQ ID NO: 91;

[0120] Sense strand: SEQ ID NO: 71, antisense strand: SEQ ID NO: 92;

[0121] Sense strand: SEQ ID NO: 72, antisense strand: SEQ ID NO: 93;

[0122] Sense strand: SEQ ID NO: 73, antisense strand: SEQ ID NO: 94;

[0123] Sense strand: SEQ ID NO: 74, antisense strand: SEQ ID NO: 95;

[0124] Sense strand: SEQ ID NO: 75, antisense strand: SEQ ID NO: 96;

[0125] Sense strand: SEQ ID NO: 76, antisense strand: SEQ ID NO: 97;

[0126] Sense strand: SEQ ID NO: 77, antisense strand: SEQ ID NO: 98;

[0127] Sense strand: SEQ ID NO: 78, antisense strand: SEQ ID NO: 99;

[0128] Sense strand: SEQ ID NO: 72, antisense strand: SEQ ID NO: 100;

[0129] Sense strand: SEQ ID NO: 72, antisense strand: SEQ ID NO: 101;

[0130] Sense strand: SEQ ID NO: 72, antisense strand: SEQ ID NO: 102;

[0131] Sense strand: SEQ ID NO: 72, antisense strand: SEQ ID NO: 103;

[0132] Sense strand: SEQ ID NO: 79, antisense strand: SEQ ID NO: 104; and

[0133] Sense strand: SEQ ID NO: 79, antisense strand: SEQ ID NO: 105.

[0134] In a second aspect, the present invention provides a vector comprising a nucleotide sequence encoding the dsRNA of the present invention.

[0135] In a third aspect, the present invention provides a cell comprising the dsRNA or vector of the present invention.

[0136] In a fourth aspect, the present invention provides a pharmaceutical composition comprising the dsRNA of the present invention, a vector or a cell, and optionally a pharmaceutically acceptable carrier or excipient.

[0137] In a fifth aspect, the present invention provides a kit comprising the dsRNA, vector or cell of the present invention.

[0138] In a sixth aspect, the present invention provides a method for reducing angiotensinogen (AGT) in a subject, comprising administering to the subject a dsRNA, vector, cell, or pharmaceutical composition of the present invention. The present invention also provides a method for treating a disease or condition that benefits from reduced angiotensinogen (AGT) expression in a subject, comprising administering to the subject a dsRNA, vector, cell, or pharmaceutical composition of the present invention. The present invention also provides a method for preventing at least one symptom in a subject suffering from a disease or condition that benefits from reduced angiotensinogen (AGT) expression, comprising administering to the subject a dsRNA, vector, cell, or pharmaceutical composition of the present invention.

[0139] In some embodiments, the disease or condition that would benefit from reduced expression of angiotensinogen (AGT) is an AGT-mediated or AGT-associated disease.

[0140] In some embodiments, the AGT-mediated or AGT-related disease is selected from the group consisting of: hypertension, ocular hypertension, glaucoma, hypertensive heart disease, hypertensive nephropathy, atherosclerosis, arteriosclerosis, vasculopathy, diabetic nephropathy, diabetic retinopathy, chronic heart failure, cardiomyopathy, diabetic cardiomyopathy, glomerulosclerosis, aortic coarctation, aortic aneurysm, ventricular fibrosis, heart failure, myocardial infarction, angina pectoris, stroke, kidney disease, renal failure, systemic sclerosis, intrauterine growth restriction (IUGR), fetal growth restriction, obesity, hepatic steatosis / fatty liver, non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD); glucose intolerance, type 2 diabetes (non-insulin-dependent diabetes mellitus) and metabolic syndrome. In some embodiments, the hypertension is selected from the group consisting of borderline hypertension, essential hypertension, secondary hypertension, isolated systolic or diastolic hypertension, pregnancy-related hypertension, diabetic hypertension, resistant hypertension, refractory hypertension, paroxysmal hypertension, renovascular hypertension, Goldblatt hypertension, pulmonary hypertension, portal hypertension, systemic venous hypertension, systolic hypertension, and unstable hypertension.

[0141] In some embodiments, the methods of the invention for treating a disease or condition that would benefit from reduced expression of angiotensinogen (AGT) in a subject, preventing at least one symptom in a patient suffering from a disease or condition that would benefit from reduced expression of angiotensinogen (AGT), or reducing angiotensinogen (AGT) in a subject comprise administering the dsRNA, vector, cell, or pharmaceutical composition subcutaneously, topically, or intravenously to the subject.

[0142] In some embodiments, the subject is a human patient. BRIEF DESCRIPTION OF THE DRAWINGS

[0143] Figure 1 shows the serum AGT-lowering effects of the test compounds in cynomolgus monkeys.

[0144] Figure 2 shows the systolic blood pressure lowering effects of the test compounds in cynomolgus monkeys.

[0145] FIG3 shows the diastolic blood pressure lowering effects of the test compounds in cynomolgus monkeys.

[0146] Figure 4 shows the effect of the test compound on lowering mean arterial pressure in cynomolgus monkeys.

[0147] Detailed Description of the Invention

[0148] The following describes the embodiments of the present invention through specific examples. Those skilled in the art will readily understand the other advantages and benefits of the present invention from the disclosure herein. The present invention may also be implemented or applied through various other specific embodiments, and the details in this specification may be modified or altered based on different perspectives and applications without departing from the spirit of the present invention.

[0149] It should be understood that the scope of protection of the present invention is not limited to the specific embodiments described below; it should also be understood that the terms used in the examples of the present invention are for describing specific embodiments rather than for limiting the scope of protection of the present invention.

[0150] Throughout the specification and claims of the present invention, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.

[0151] When the embodiment provides a numerical range, it should be understood that, unless otherwise specified in the present invention, the two endpoints of each numerical range and any numerical value between the two endpoints can be selected. Unless otherwise defined, all technical and scientific terms used in the present invention have the same meaning as those generally understood by those skilled in the art. In addition to the specific methods, equipment, and materials used in the examples, according to the grasp of the prior art by those skilled in the art and the record of the present invention, any method, equipment, and material of the prior art similar or equivalent to the methods, equipment, and materials described in the examples of the present invention can also be used to realize the present invention, and all belong to the protection scope of the present invention. The following describes embodiments of the present invention in more detail.

[0152] definition

[0153] "Double-stranded region" herein refers to a region comprising two nucleic acid strands that are antiparallel and complementary or substantially complementary.

[0154] As used herein, the term "double-stranded RNA" or "dsRNA" refers to a ribonucleic acid molecule or a ribonucleic acid molecule complex comprising a double-stranded region as defined above. The two parts forming the double-stranded region can be two different parts of a larger RNA molecule, or they can be separate RNA molecules.

[0155] When the two parts are separate RNA molecules, the dsRNA herein is referred to as small interfering RNA (siRNA) or short interfering RNA (siRNA).

[0156] When the two moieties are two distinct parts of a larger molecule, that is, when the 3' end of one moiety is linked to the 5' end of the other moiety by one or more uninterrupted nucleotides in between to form a double-stranded region, the uninterrupted nucleotides used to connect the two moieties are called a "hairpin." When the two moieties are covalently linked to form a double-stranded region by a method other than a hairpin, the connection structure is called a "linker." When such dsRNA is introduced into cells, it is cleaved into siRNA by an intracellular endoribonuclease called Dicer.

[0157] The term "siRNA" herein refers to a class of double-stranded RNA molecules comprising a sense strand and an antisense strand that can mediate the silencing of a target RNA (e.g., mRNA, e.g., a transcript of a gene encoding a protein) that is complementary or substantially complementary to the antisense strand. siRNA is typically double-stranded, comprising an antisense strand that is complementary to the target RNA, and a sense strand that is complementary or substantially complementary to the antisense strand. For convenience, such mRNA is also referred to herein as mRNA to be silenced. Such a gene is also referred to as a target gene. Typically, the RNA to be silenced is an endogenous gene or a pathogen gene. In addition, RNA (e.g., tRNA) and viral RNA other than mRNA can also be targeted.

[0158] As used herein, the term "antisense strand" refers to the strand of a dsRNA, particularly a siRNA, that contains a region that is fully complementary or substantially complementary to a target sequence.

[0159] As used herein, the term "complementary region" refers to a region on the antisense strand that is completely or substantially complementary to the target mRNA sequence. In the case where the complementary region is not completely complementary to the target sequence, mispairing can be located in the interior or terminal regions of the molecule. Typically, the most tolerated mispairing is located in the terminal regions, for example, within 5, 4, 3, 2 or 1 nucleotides at 5' and / or 3' ends. The antisense strand portion that is most sensitive to mispairing is referred to as a "seed region." For example, in a siRNA comprising a 19nt chain, the 19th position (from 5' to 3') can tolerate some mispairing.

[0160] As used herein, the term "complementary" refers to the ability of a first polynucleotide to hybridize to a second polynucleotide under certain conditions, such as stringent conditions. For example, stringent conditions may include 400 mM NaCl, 40 mM PIPES pH 6.4, 1 mM EDTA at 50° C. or 70° C. for 12-16 hours.

[0161] As used herein, "complementary" sequences, insofar as they meet the above requirements for their ability to hybridize, may also include or be formed entirely from non-Watson-Crick base pairs and / or base pairs formed from non-natural and modified nucleotides. Such non-Watson-Crick base pairs include, but are not limited to, G:U wobble base pairing or Hoogstein base pairing.

[0162] As used herein, a polynucleotide that is "at least partially complementary" or "substantially complementary" to a messenger RNA (mRNA) refers to a polynucleotide that is substantially complementary to a contiguous portion of an mRNA of interest (e.g., an mRNA encoding AGT). For example, a polynucleotide is complementary to at least a portion of an AGT mRNA if the sequence is substantially complementary to a non-interrupted portion of an mRNA encoding AGT.

[0163] As used herein, the terms "complementary," "fully complementary," and "substantially complementary" can be used with respect to base pairing between the sense and antisense strands of a dsRNA, particularly an siRNA, or between the antisense strand of a dsRNA, particularly an siRNA, and a target sequence.

[0164] As used herein, the term "sense strand" refers to the strand of an siRNA that includes a region that is substantially complementary to a region defined herein as the antisense strand.

[0165] A "nucleoside" is a compound composed of a purine or pyrimidine base and ribose or deoxyribose; a "nucleotide" is a compound composed of a purine or pyrimidine base, ribose or deoxyribose, and phosphate; an "oligonucleotide" is a nucleic acid molecule (RNA or DNA) having, for example, fewer than 100, 200, 300, or 400 nucleotides in length.

[0166] "Bases" are the fundamental building blocks of nucleosides, nucleotides, and nucleic acids. They contain nitrogen and are also called "nitrogenous bases." Unless otherwise specified, the capital letters A, U, T, G, and C represent the bases of nucleotides, representing adenine, uracil, thymine, guanine, and cytosine, respectively.

[0167] As used herein, the term "nucleotide overhang" refers to at least one unpaired nucleotide that protrudes from the double-stranded region of an siRNA. For example, when the 3'-end of a chain of an siRNA extends beyond the 5'-end of another chain or vice versa, there is a nucleotide overhang. The siRNA can comprise an overhang with at least one nucleotide, an overhang with at least two nucleotides, an overhang with at least three nucleotides, an overhang with at least four nucleotides, an overhang with at least five nucleotides or more. The nucleotide overhang can comprise or consist of nucleotides / modified nucleotides (including deoxynucleotides / nucleosides). One or more overhangs can be on a sense strand or an antisense strand or any combination thereof. An overhang with one or more nucleotides can be present on the 5'-end, the 3'-end or both ends of the antisense or sense strand of the siRNA.

[0168] "Blunt end" or "blunt end" or "blunt end" means that there are no unpaired nucleotides at that end of the double-stranded siRNA, i.e., no nucleotide overhangs. A "blunt-ended siRNA" is a siRNA that is double-stranded throughout the entire length of the siRNA, i.e., there are no nucleotide overhangs at either end of the molecule.

[0169] Substantially all of the nucleotides of the dsRNA (particularly siRNA) of the present invention are modified. For example, substantially all of the nucleotides of the sense strand are modified nucleotides, or substantially all of the nucleotides of the antisense strand are modified nucleotides, or substantially all of the nucleotides of both the sense strand and the antisense strand are modified nucleotides. In other embodiments of the present invention, all of the nucleotides of the dsRNA (particularly siRNA) of the present invention are modified nucleotides. For example, all of the nucleotides of the sense strand are modified nucleotides, or all of the nucleotides of the antisense strand are modified nucleotides, or all of the nucleotides of both the sense strand and the antisense strand are modified nucleotides. As used herein, "substantially all of the nucleotides are modified" means that most of the nucleotides of the dsRNA (particularly siRNA) of the present invention are modified, but not all of the nucleotides are modified, and can include no more than 5, 4, 3, 2 or 1 unmodified nucleotides.

[0170] As used herein, "modified nucleotides" include, but are not limited to, 2'-O-alkyl modified nucleotides (e.g., 2'-O-methyl modified nucleotides, 2'-methoxyethyl modified nucleotides), 2'-fluoro modified nucleotides, 2'-deoxy-modified nucleotides, SCP modifications, inosine ribonucleotides, abasic nucleotides, inverted abasic deoxyribonucleotides, nucleotides containing a phosphorothioate group, vinyl phosphate modified nucleotides, locked nucleotides, unlocked nucleotides, 2'-amino-modified nucleotides, 2'-C-alkyl-modified nucleotides, 2'-O-allyl modified nucleotides, Morpholino nucleotides, phosphoramidates, nucleotides containing unnatural bases, terminal nucleotides attached to a cholesterol derivative or a dodecanoic acid didecylamide group, deoxyribonucleotides, 3'-terminal deoxythymidine (dT) nucleotides, conformationally restricted nucleotides, restricted ethyl nucleotides, 2'-hydroxyl modified nucleotides, nucleotides containing a methylphosphonic acid group, nucleotides containing a 5'-phosphate, nucleotides containing a 5'-phosphate mimetic, glycol-modified nucleotides (GNA), modifications of phosphorothioate internucleotide linkages, and 2-O-(N-methylacetamide) modified nucleotides, etc.

[0171] For example, a "2'-fluoro modified nucleotide" refers to a nucleotide in which the hydroxyl group at the 2' position of the ribose group is replaced by fluorine. A "2'-O-methyl modified nucleotide" refers to a nucleotide in which the 2'-hydroxyl group at the ribose group is replaced by a methoxy group.

[0172] A "phosphorothioate-containing nucleotide" refers to a nucleotide in which one or more oxygen atoms on the phosphate group of the nucleotide are replaced by a sulfur atom. A "phosphorothioate internucleotide linkage modification" refers to a modification in which two adjacent nucleotides are linked by a phosphorothioate.

[0173] In some embodiments, the sense strand of the dsRNA (particularly siRNA) of the present disclosure has a modification of one or two phosphorothioate internucleotide linkages located at positions 1 to 5 (counting from the 5' end) and / or has a modification of one or two phosphorothioate internucleotide linkages located at positions 1 to 5 (counting from the 3' end), and / or the antisense strand of the dsRNA (particularly siRNA) of the present disclosure has a modification of one or two phosphorothioate internucleotide linkages located at positions 1 to 5 (counting from the 5' end) and / or has a modification of one or two phosphorothioate internucleotide linkages located at positions 1 to 5 (counting from the 3' end).

[0174] In some embodiments, the sense strand of the dsRNA (particularly siRNA) of the present disclosure has a modification of one or two phosphorothioate internucleotide linkages at positions 1 to 4 (counting from the 5' end) and / or has a modification of one or two phosphorothioate internucleotide linkages at positions 1 to 4 (counting from the 3' end), and / or the antisense strand of the dsRNA (particularly siRNA) of the present disclosure has a modification of one or two phosphorothioate internucleotide linkages at positions 1 to 4 (counting from the 5' end) and / or has a modification of one or two phosphorothioate internucleotide linkages at positions 1 to 4 (counting from the 3' end).

[0175] In some embodiments, the sense strand of the dsRNA (particularly siRNA) of the present disclosure has a modification of one or two phosphorothioate internucleotide linkages at positions 1 to 3 (counting from the 5' end) and / or has a modification of one or two phosphorothioate internucleotide linkages at positions 1 to 3 (counting from the 3' end), and / or the antisense strand of the dsRNA (particularly siRNA) of the present disclosure has a modification of one or two phosphorothioate internucleotide linkages at positions 1 to 3 (counting from the 5' end) and / or has a modification of one or two phosphorothioate internucleotide linkages at positions 1 to 3 (counting from the 3' end).

[0176] In some embodiments, the sense strand of the dsRNA (particularly siRNA) of the present disclosure has a modification of one or two phosphorothioate internucleotide linkages at positions 1 and 2 (counting from the 5' end) and / or has a modification of one or two phosphorothioate internucleotide linkages at positions 1 and 2 (counting from the 3' end), and / or the antisense strand of the dsRNA (particularly siRNA) of the present disclosure has a modification of one or two phosphorothioate internucleotide linkages at positions 1 to 2 (counting from the 5' end) and / or has a modification of one or two phosphorothioate internucleotide linkages at positions 1 to 2 (counting from the 3' end).

[0177] In some embodiments, the sense strand of a dsRNA (particularly siRNA) of the present disclosure has a modification of one or two phosphorothioate internucleotide linkages at positions 1 and 2 (counting from the 5' end) and / or has a modification of one or two phosphorothioate internucleotide linkages at positions 1 and 2 (counting from the 3' end), and / or the antisense strand of a dsRNA (particularly siRNA) of the present disclosure has a modification of one or two phosphorothioate internucleotide linkages at positions 1 to 2 (counting from the 5' end) and / or has a modification of one or two phosphorothioate internucleotide linkages at positions 1 to 2 (counting from the 3' end), wherein the 3' end of the sense strand is linked to a ligand moiety, and the 3' terminal nucleotide of the sense strand is linked to the ligand moiety via a phosphate linkage.

[0178] In some embodiments, the sense strand of a dsRNA (particularly siRNA) of the present disclosure has a modification of one or two phosphorothioate internucleotide linkages at positions 1 and 2 (counting from the 5' end) and / or has a modification of one or two phosphorothioate internucleotide linkages at positions 1 and 2 (counting from the 3' end), and / or the antisense strand of a dsRNA (particularly siRNA) of the present disclosure has a modification of one or two phosphorothioate internucleotide linkages at positions 1 to 2 (counting from the 5' end) and / or has a modification of one or two phosphorothioate internucleotide linkages at positions 1 to 2 (counting from the 3' end), wherein the 3' end of the sense strand is linked to a ligand moiety, and the 3' terminal nucleotide of the sense strand is linked to the ligand moiety via a phosphorothioate linkage.

[0179] As used herein, "ligand moiety" refers to a chemical moiety conjugated to a dsRNA (particularly siRNA) that is capable of altering the distribution, targeting, or lifespan of the dsRNA (particularly siRNA). In some embodiments, the ligand moiety provides enhanced affinity for a selected target (e.g., a molecule, a cell or cell type, a compartment (e.g., a cell or organ compartment, a tissue, an organ, or a region of the body)) compared to, for example, an siRNA without this ligand moiety. In some embodiments, the ligand moiety targets the asialoglycoprotein receptor (ASGPR) on hepatocytes. Binding of the ligand moiety to the ASGPR mediates internalization via clathrin-coated vesicles. Endosome maturation results in a decrease in lysosomal pH, which promotes the dissociation of the ligand-receptor complex, thereby releasing the dsRNA (particularly siRNA). Conjugation of the ligand moiety targeting the asialoglycoprotein receptor (ASGPR) on hepatocytes results in increased efficacy and stability of the dsRNA (particularly siRNA) in vivo or within a cell. This facilitates subcutaneous administration of the dsRNA (particularly siRNA).

[0180] As used herein, the term "inhibit" is used interchangeably with "reduce," "silence," "downregulate," and other similar terms and includes any level of inhibition.

[0181] The phrase "inhibiting the expression of angiotensinogen (AGT)" refers to inhibiting the expression of any AGT gene, as well as variants or mutants of the AGT gene. Thus, the AGT gene can be a wild-type AGT gene, a mutant AGT gene, or a transgenic AGT gene in the context of a genetically manipulated cell, cell group, or organism.

[0182] "Inhibiting the expression of the AGT gene" includes any level of inhibition of the AGT gene, such as at least partial inhibition of AGT gene expression. AGT gene expression can be assessed based on the level or level change of any variable related to AGT gene expression, such as AGT mRNA level, AGT protein level. This level can be assessed in a single cell or in a group of cells (including, for example, a sample derived from a subject).

[0183] Inhibition can be assessed by a reduction in the absolute or relative level of one or more variables associated with AGT expression compared to a control level. The control level can be any type of control level utilized in the art, such as a pre-dose baseline level or a level determined from a similar untreated or controlled (e.g., buffer-only or inert agent-only) treated subject, cell, or sample.

[0184] "Hydroxy protecting group" refers to a group that can prevent the hydroxyl group from chemical reaction and can be removed under specific conditions to restore the hydroxyl group. It mainly includes silane type protecting groups, acyl type protecting groups or ether type protecting groups, preferably the following: trimethylsilyl (TMS), triethylsilyl (TES), dimethylisopropylsilyl (DMIPS), diethylisopropylsilyl (DEIPS), tert-butyldimethylsilyl (TBDMS), tert-butyldiphenylsilyl (TBDPS), triisopropylsilyl (TIPS), acetyl (Ac), chloroacetyl, dichloroacetyl, trichloroacetyl, trifluoroacetyl (TFA), benzoyl, p-methoxybenzoyl, 9-fluorenylmethoxycarbonyl ( Fmoc), allyloxycarbonyl (Alloc), 2,2,2-trichloroethoxycarbonyl (Troc), benzyloxycarbonyl (Cbz), tert-butyloxycarbonyl (Boc), benzyl (Bn), p-methoxybenzyl (PMB), allyl, triphenylmethyl (Tr), bis-p-methoxytrityl (DMTr), methoxymethyl (MOM), phenoxymethyl (BOM), 2,2,2-trichloroethoxymethyl, 2-methoxyethoxymethyl (MEM), methylthiomethyl (MTM), p-methoxybenzyloxymethyl (PMBM).

[0185] "Halo" or "halogen" refers to fluorine (F), chlorine (Cl), bromine (Br) and iodine (I).

[0186] “C 1-6 "Haloalkyl" refers to the above-mentioned "C 1-6 Alkyl", which is substituted by one or more halogen groups. In some embodiments, C 1-4 Halogenated alkyl is particularly preferred, more preferably C 1-2Haloalkyl. Exemplary haloalkyl groups include, but are not limited to, -CF3, -CH2F, -CHF2, -CHFCH2F, -CH2CHF2, -CF2CF3, -CCl3, -CH2Cl, -CHCl2, 2,2,2-trifluoro-1,1-dimethyl-ethyl, and the like. The haloalkyl group can be substituted at any available point of attachment, for example, with 1 to 5 substituents, 1 to 3 substituents, or 1 substituent.

[0187] “C 1-6 "Alkylene" refers to the removal of C 1-6 In some embodiments, C 1-4 Alkylene, C 2-4 Alkylene and C 1-2 Alkylene is preferred. Unsubstituted alkylene includes, but is not limited to, methylene (-CH2-), ethylene (-CH2CH2-), propylene (-CH2CH2CH2-), butylene (-CH2CH2CH2CH2-), pentylene (-CH2CH2CH2CH2CH2-), hexylene (-CH2CH2CH2CH2CH2CH2-), and the like. Exemplary substituted alkylenes, for example, alkylenes substituted with one or more alkyl (methyl) groups, include, but are not limited to, substituted methylene (-CH(CH3)-, -C(CH3)2-), substituted ethylene (-CH(CH3)CH2-, -CH2CH(CH3)-, -C(CH3)2CH2-, -CH2C(CH3) 2- ), substituted propylene (-CH(CH3)CH2CH2-, -CH2CH(CH3)CH2-, -CH2CH2CH(CH3)-, -C(CH3)2CH2CH2-, -CH2C(CH3)2CH2-, -CH2CH2C(CH3)2-), and the like.

[0188] As used herein, the term "vector" refers to a nucleic acid molecule that is capable of amplifying or expressing another nucleic acid to which it is linked. The "vector" herein is generally a vector that can replicate autonomously in a host cell, preferably a multicopy vector. In addition, the vector generally has markers such as antibiotic resistance genes for selecting transformants. In addition, the vector may have a promoter and / or terminator for expressing the introduced gene. The vector may be, for example, a vector derived from a bacterial plasmid, a viral vector, a vector derived from a yeast plasmid, a vector derived from a bacteriophage, a cosmid, a phagemid, etc.

[0189] As used herein, the terms "treat", "treat", and the like refer to the administration of an agent or the performance of a procedure in order to obtain an effect. These effects may be preventive in terms of completely or partially preventing a disease or its symptoms, and / or may be therapeutic in terms of affecting a partial or complete cure of a disease and / or disease symptoms. As used herein, "treatment" may include the treatment of a disease or condition (e.g., cancer) in a mammal, particularly a human, and includes: (a) preventing the occurrence of the disease or disease symptoms in a subject susceptible to the disease but not yet diagnosed as having the disease (e.g., including diseases that may be associated with or caused by the primary disease); (b) inhibiting the disease, i.e., preventing its development; (c) alleviating the disease, i.e., causing regression of the disease. Treatment may refer to any reference to success in treating, ameliorating, or preventing cancer, including any objective or subjective parameter, such as elimination; alleviation; reducing symptoms or making the disease condition more tolerable for the patient; slowing the rate of deterioration or decline; or reducing the end point of deterioration. Treatment or improvement of symptoms is based on one or more objective or subjective parameters; including the results of a doctor's examination. Thus, the term "treatment" includes administering an antibody, composition, or conjugate disclosed herein to prevent, delay, alleviate, arrest, or inhibit the development of symptoms or conditions associated with a disease (e.g., cancer). The term "therapeutic effect" refers to the reduction, elimination, or prevention of a disease, disease symptom, or disease side effect in a subject.

[0190] The term "effective amount" as used herein refers to an amount that, when administered to a subject for treating a disease, is sufficient to effect such treatment.

[0191] As used herein, the term "subject" refers to any mammalian subject for whom diagnosis, treatment, or therapy is desired. "Mammal" for therapeutic purposes refers to any animal classified as a mammal, including humans, livestock, and laboratory, zoo, sport, or pet animals, such as dogs, horses, cats, cows, sheep, goats, pigs, mice, rats, rabbits, guinea pigs, monkeys, and the like.

[0192] I.dsRNA

[0193] The present invention provides a double-stranded RNA (dsRNA) for inhibiting the expression of angiotensinogen (AGT) in a cell, wherein the dsRNA comprises a sense strand and an antisense strand forming a double-stranded region, wherein the length of the sense strand and the antisense strand are each independently 15-30 nucleotides, and the antisense strand comprises a nucleotide sequence of at least 15 consecutive nucleotides of the nucleotide sequence shown in any one of SEQ ID NOs: 21-40.

[0194] In some embodiments, the double-stranded region formed by the sense strand and the antisense strand is fully complementary. In other embodiments, the double-stranded region formed by the sense strand and the antisense strand is substantially complementary and may comprise 1, 2, 3, 4 or 5 non-complementary sites.

[0195] In some specific embodiments, the sense strand comprises a nucleotide sequence of at least 15 consecutive nucleotides of the nucleotide sequence shown in any one of SEQ ID NOs: 1-20.

[0196] In some embodiments, the sense strand and the antisense strand are each independently 15-27 nucleotides in length, preferably 18-25 nucleotides, and more preferably 19-21 nucleotides in length.

[0197] In some embodiments, the length of the double-stranded region is 15-25 nucleotide pairs, preferably 16-23 nucleotide pairs, and more preferably 18-20 nucleotide pairs.

[0198] In some embodiments, the dsRNA of the present invention is siRNA.In other embodiments, a hairpin loop is formed between the sense strand and the antisense strand of the dsRNA of the present invention.

[0199] One or both of the sense strand and the antisense strand comprise a 3' overhang and / or a 5' overhang having at least 1 nucleotide. In some embodiments, one or both of the sense strand and the antisense strand comprise a 3' overhang and / or a 5' overhang having at least 1 nucleotide. In some specific embodiments, one or both of the sense strand and the antisense strand comprise a 3' overhang and / or a 5' overhang having 1 nucleotide. In some specific embodiments, one or both of the sense strand and the antisense strand comprise a 3' overhang and / or a 5' overhang having 2 nucleotides. In some specific embodiments, one or both of the sense strand and the antisense strand comprise a 3' overhang and / or a 5' overhang having 3 nucleotides. In some specific embodiments, one or both of the sense strand and the antisense strand comprise a 3' overhang and / or a 5' overhang having 4 nucleotides.

[0200] In some specific embodiments, the antisense strand comprises a 3' overhang and / or a 5' overhang of 1 nucleotide. In some embodiments, the antisense strand comprises a 3' overhang and / or a 5' overhang of 2 nucleotides. In some embodiments, the antisense strand comprises a 3' overhang and / or a 5' overhang of 3 nucleotides. In some embodiments, the antisense strand comprises a 3' overhang and / or a 5' overhang of 4 nucleotides. In some preferred embodiments, the antisense strand has a 3' overhang and / or a 5' overhang of at least 2 nucleotides.

[0201] Preferably, the antisense strand comprises a 3' overhang and / or a 5' overhang of 2 nucleotides.

[0202] In some embodiments, the sense strand and the antisense strand are the same length.

[0203] In some embodiments, the full length of the sense strand is complementary to the full length of the antisense strand to form a double strand, ie, has blunt ends.

[0204] In other embodiments, the sense strand and the antisense strand are the same length, and a portion of the sense strand is complementary to a portion of the antisense strand, i.e., both the sense strand and the antisense strand have a 5' overhang. In some embodiments, the sense strand and the antisense strand are different lengths. In a preferred embodiment, the 5' end of the antisense strand has an overhang of at least 1 nucleotide, more preferably an overhang of 2 or 3 nucleotides.

[0205] The dsRNA of the present invention is included in a dsRNA having a nucleotide overhang (that is, a reagent with an overhang and a blunt end) at one end or at both ends. For example, the 5'-end of the sense strand of the dsRNA comprises an overhang with one or more nucleotides and the 3'-end of the sense strand comprises an overhang with one or more nucleotides. For example, the 5'-end of the antisense strand of the dsRNA comprises an overhang with one or more nucleotides and the 3'-end of the antisense strand comprises an overhang with one or more nucleotides. For example, the 5'-end of the sense strand of the dsRNA comprises an overhang with one or more nucleotides and the 5'-end of the antisense strand comprises an overhang with one or more nucleotides. For example, the 3'-end of the sense strand of the dsRNA comprises an overhang with one or more nucleotides and the 3'-end of the antisense strand comprises an overhang with one or more nucleotides. For example, the 5'-end of the sense strand of the dsRNA comprises an overhang with one or more nucleotides and the 3'-end of the antisense strand comprises an overhang with one or more nucleotides. For example, the 5'-end of the sense strand of the dsRNA comprises an overhang with one or more nucleotides and the 3'-end of the antisense strand comprises an overhang with one or more nucleotides. For example, the 3'-end of the sense strand of a dsRNA comprises an overhang of one or more nucleotides and the 3'-end of the sense strand comprises a blunt end. For example, the 5'-end of the antisense strand of a dsRNA comprises an overhang of one or more nucleotides and the 3'-end of the antisense strand comprises a blunt end. For example, the 3'-end of the antisense strand of a dsRNA comprises an overhang of one or more nucleotides and the 5'-end of the antisense strand comprises a blunt end.

[0206] In some preferred embodiments, the 3'-end of the antisense strand of the dsRNA of the invention comprises an overhang of one or more nucleotides and the 5'-end of the antisense strand comprises a blunt end. In some more preferred embodiments, the 3'-end of the antisense strand of the dsRNA of the invention comprises an overhang of 1, 2, 3, or 4 nucleotides and the 5'-end of the antisense strand comprises a blunt end. In some more preferred embodiments, the 3'-end of the antisense strand of the dsRNA of the invention comprises an overhang of 2 nucleotides and the 5'-end of the antisense strand comprises a blunt end.

[0207] In some embodiments, the antisense strand comprises a nucleotide sequence of at least 16 consecutive nucleotides of the nucleotide sequence shown in any one of SEQ ID NOs: 21-40, a nucleotide sequence of at least 17 consecutive nucleotides, a nucleotide sequence of at least 18 consecutive nucleotides, a nucleotide sequence of at least 19 consecutive nucleotides, or a nucleotide sequence of at least 20 consecutive nucleotides. Preferably, the antisense strand comprises the nucleotide sequence shown in any one of SEQ ID NOs: 21-40.

[0208] In some embodiments, the sense strand comprises a nucleotide sequence of at least 16 consecutive nucleotides, a nucleotide sequence of at least 17 consecutive nucleotides, or a nucleotide sequence of at least 18 consecutive nucleotides of any one of the nucleotide sequences shown in SEQ ID NOs: 1-20. Preferably, the sense strand comprises the nucleotide sequence shown in any one of SEQ ID NOs: 1-20.

[0209] In some embodiments, the dsRNA comprises any pair of paired sense strand sequences and antisense strand sequences shown in Table 3.

[0210] II. Modification of Nucleotides

[0211] In some embodiments, substantially all of the nucleotides of the sense strand and substantially all of the nucleotides of the antisense strand are modified nucleotides. In some embodiments, at least 80% of the nucleotides of the sense strand are modified nucleotides, and / or at least 80%, at least 85%, at least 90%, at least 92%, at least 95% of the nucleotides of the antisense strand are modified nucleotides. In some embodiments, at least 80% of the nucleotides of the antisense strand are modified nucleotides, and / or at least 80%, at least 85%, at least 90%, at least 92%, at least 95% of the nucleotides of the sense strand are modified nucleotides.

[0212] In some embodiments, all nucleotides of the sense strand are modified nucleotides and / or all nucleotides of the antisense strand are modified nucleotides.

[0213] The nucleotide modification described in the present invention may be a modification on the phosphate group, ribose group and / or base group of the nucleotide.

[0214] In some specific embodiments, the sense strand and the antisense strand each independently comprise one or more nucleotide modifications selected from the group consisting of 2'-O-alkyl modified nucleotides (e.g., 2'-O-methyl modified nucleotides), 2'-methoxyethyl modified nucleotides, 2'-fluoro modified nucleotides, 2'-deoxy-modified nucleotides, inosine ribonucleotides, abasic nucleotides, inverted abasic deoxyribonucleotides, nucleotides containing a thiophosphate group, vinyl phosphate modified nucleotides, locked nucleotides, unlocked nucleotides, 2'-amino-modified nucleotides, 2'-C-alkyl-modified nucleotides, 2'-O-olefin modified nucleotides, Propyl-modified nucleotides, morpholino nucleotides, phosphoramidates, nucleotides containing unnatural bases, terminal nucleotides linked to a cholesteryl derivative or a dodecyldiamide group, deoxyribonucleotides, 3'-terminal deoxythymidine (dT) nucleotides, conformationally restricted nucleotides, restricted ethyl nucleotides, 2'-hydroxyl-modified nucleotides, nucleotides containing a methylphosphonic acid group, nucleotides containing a 5'-phosphate, nucleotides containing a 5'-phosphate mimetic, SCP modifications, ethylene glycol-modified nucleotides (GNA), modifications of phosphorothioate internucleotide linkages, and 2-O-(N-methylacetamide)-modified nucleotides.

[0215] In some preferred embodiments, the sense strand and the antisense strand each independently comprise one or more nucleotide modifications selected from the group consisting of a 2'-O-methyl modification, a 2'-fluoro modification, an SCP modification, and a modification of a phosphorothioate internucleotide linkage.

[0216] In some preferred embodiments, the sense strand and / or the antisense strand comprises at least 2 2'-fluoro-modified nucleotides. In some preferred embodiments, the sense strand and / or the antisense strand comprises at least 8 2'-O-methyl-modified nucleotides. In some preferred embodiments, the 3' end and / or the 5' end of the sense strand and / or the antisense strand comprises 1-5 phosphorothioate internucleotide linkages, preferably 2-3 phosphorothioate internucleotide linkages. In some embodiments, the sense strand and / or the antisense strand comprises adenine deoxyribonucleotides, thymine deoxyribonucleotides, guanine deoxyribonucleotides and / or cytosine deoxyribonucleotides. In a more preferred embodiment, the sense strand and / or the antisense strand comprises thymine deoxyribonucleotides. In a most preferred embodiment, the sense strand comprises thymine deoxyribonucleotides.

[0217] In some embodiments, the antisense strand is 21 nucleotides in length and has

[0218] (i) (counting from the 5' end) 2'-O-methyl modified nucleotides at positions 1, 3, 5, 9, 11, 13, 15, 17, 19 and 21, and 2'-fluoro modified nucleotides at positions 2, 4, 6, 8, 10, 12, 14, 16, 18 and 20; and / or

[0219] (ii) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, between nucleotide positions 2 and 3, between nucleotide positions 19 and 20, and between nucleotide positions 20 and 21 (counting from the 5' end).

[0220] In some embodiments, the antisense strand is 21 nucleotides in length and has

[0221] (i) (counting from the 5' end) 2'-O-methyl modified nucleotides at positions 1, 3, 5, 9, 11, 13, 15, 17, 19, 20 and 21, and 2'-fluoro modified nucleotides at positions 2, 4, 6, 8, 10, 12, 14, 16 and 18; and / or

[0222] (ii) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, between nucleotide positions 2 and 3, between nucleotide positions 19 and 20, and between nucleotide positions 20 and 21 (counting from the 5' end).

[0223] In some embodiments, the antisense strand is 21 nucleotides in length and has

[0224] (i) 2'-O-methyl modified nucleotides at positions 3, 4, 6, 8, 9, 10, 11, 13, 15, 16, 17, 18, 19, 20 and 21 (counting from the 5' end);

[0225] (ii) a 2'-fluoro-modified nucleotide at position 14 (counting from the 5' end);

[0226] (iii) 2′-deoxy modifications at positions 2, 5, 7, and 12 (counting from the 5′ end);

[0227] (iv) an SCP modification at position 1 (counting from the 5' end); and / or

[0228] (v) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, between nucleotide positions 2 and 3, between nucleotide positions 19 and 20, and between nucleotide positions 20 and 21 (counting from the 5' end).

[0229] In some embodiments, the antisense strand is 21 nucleotides in length and has

[0230] (i) 2'-O-methyl modified nucleotides at positions 3, 5, 9, 11, 13, 15, 17, 19, 20 and 21 (counting from the 5' end);

[0231] (ii) 2′-fluoro-modified nucleotides at positions 2, 4, 6, 8, 10, 12, 14, 16, and 18 (counting from the 5′ end);

[0232] (iii) GNA modification at position 7 (counting from the 5′ end);

[0233] (iv) an SCP modification at position 1 (counting from the 5' end); and / or

[0234] (v) Phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, between nucleotide positions 2 and 3, between nucleotide positions 19 and 20, and between nucleotide positions 20 and 21 (counting from the 5' end).

[0235] In some embodiments, the sense strand has a length of 19 nucleotides and has:

[0236] (i) 2'-O-methyl modified nucleotides at positions 1 to 6, 10 to 19 (counting from the 5' end), and 2'-fluoro modified nucleotides at positions 7-9; and / or

[0237] (ii) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, between nucleotide positions 2 and 3, and between nucleotide positions 18 and 19 (counting from the 5' end).

[0238] In some embodiments, the antisense strand comprises a sequence selected from any one of SEQ ID NOs: 81-105.

[0239] In some embodiments, the sense strand comprises a sequence selected from any one of SEQ ID NOs: 41-59. In some preferred embodiments, the dsRNA comprises a paired modified sense strand sequence and a modified antisense strand sequence as shown in any one of Table 6.

[0240] In some embodiments, the 3' end of the sense strand is modified to attach a ligand. In some specific embodiments, the sense strand comprises a sequence selected from any one of SEQ ID NOs: 113-131.

[0241] In some preferred embodiments, the dsRNA comprises any one pair of a modified sense strand sequence and a modified antisense strand sequence selected from the following:

[0242] Sense strand: SEQ ID NO: 113, antisense strand: SEQ ID NO: 81;

[0243] Sense strand: SEQ ID NO: 114, antisense strand: SEQ ID NO: 82;

[0244] Sense strand: SEQ ID NO: 115, antisense strand: SEQ ID NO: 83;

[0245] Sense strand: SEQ ID NO: 116, antisense strand: SEQ ID NO: 84;

[0246] Sense strand: SEQ ID NO: 117, antisense strand: SEQ ID NO: 85;

[0247] Sense strand: SEQ ID NO: 118, antisense strand: SEQ ID NO: 86;

[0248] Sense strand: SEQ ID NO: 119, antisense strand: SEQ ID NO: 87;

[0249] Sense strand: SEQ ID NO: 120, antisense strand: SEQ ID NO: 88;

[0250] Sense strand: SEQ ID NO: 121, antisense strand: SEQ ID NO: 89;

[0251] Sense strand: SEQ ID NO: 122, antisense strand: SEQ ID NO: 90;

[0252] Sense strand: SEQ ID NO: 123, antisense strand: SEQ ID NO: 91;

[0253] Sense strand: SEQ ID NO: 124, antisense strand: SEQ ID NO: 92;

[0254] Sense strand: SEQ ID NO: 125, antisense strand: SEQ ID NO: 93;

[0255] Sense strand: SEQ ID NO: 126, antisense strand: SEQ ID NO: 94;

[0256] Sense strand: SEQ ID NO: 127, antisense strand: SEQ ID NO: 95;

[0257] Sense strand: SEQ ID NO: 128, antisense strand: SEQ ID NO: 96;

[0258] Sense strand: SEQ ID NO: 129, antisense strand: SEQ ID NO: 97;

[0259] Sense strand: SEQ ID NO: 130, antisense strand: SEQ ID NO: 98; and

[0260] Sense strand: SEQ ID NO: 131, antisense strand: SEQ ID NO: 99.

[0261] III. Ligand

[0262] The dsRNA of the present invention is further conjugated to a ligand moiety comprising N-acetylgalactosamine. In preferred embodiments, the sense strand of the dsRNA is conjugated to the ligand moiety. In some embodiments, the 3' end of the sense strand is conjugated to the ligand moiety. In other embodiments, the 5' end of the sense strand is conjugated to the ligand moiety.

[0263] In some embodiments, the ligand moiety comprises a conjugate group represented by formula (X'):

[0264] in,

[0265] Indicates the position where it is linked to the dsRNA;

[0266] Q is independently H,

[0267] Wherein L1 is a chemical bond, -CH2-, -CH2CH2-, -C(O)-, -CH2O-, -CH2O-CH2CH2O- or -NHC(O)-(CH2NHC(O)) a -;

[0268] L2 is a chemical bond or -CH2CH2C(O)-;

[0269] L3 is a chemical bond, -(NHCH2CH2) b -、-(NHCH2CH2CH2) b - or -C(O)CH2-;

[0270] L4 is -(OCH2CH2) c -、-(OCH2CH2CH2) c -、-(OCH2CH2CH2CH2) c -、-(OCH2CH2CH2CH2CH2) c -or-NHC(O)-(CH2) d -;

[0271] Where a = 0, 1, 2 or 3;

[0272] b = 1, 2, 3, 4, or 5;

[0273] c = 1, 2, 3, 4, or 5;

[0274] d = 1, 2, 3, 4, 5, 6, 7, or 8;

[0275] L is a chemical bond, -CH2O- or -NHC(O)-;

[0276] L' is a chemical bond, -C(O)NH-, -NHC(O)- or -O(CH2CH2O) e -;

[0277] Where e is 1, 2, 3, 4 or 5;

[0278] T is a chemical bond, -CH2-, -C(O)-, -M-, -CH2-M- or -C(O)-M-;

[0279] Where M is

[0280] R1 and R2 together form -CH2CH2O- or -CH2CH(R)-O-, and R3 is H;

[0281] Or R1 and R3 together form -C 1-2 Alkylene-, and R2 is H;

[0282] wherein R is -OR', -CH2OR' or -CH2CH2OR', wherein R' is H, a hydroxyl protecting group or a solid phase support, and the hydroxyl protecting group is preferably -C(O)CH2CH2C(O)OH or 4,4'-dimethoxytrityl;

[0283] m = 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;

[0284] n=0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.

[0285] In some embodiments, the conjugated group is represented by formula (I'):

[0286] in,

[0287] Indicates the position where it is linked to the dsRNA;

[0288] Q is independently H,

[0289] Wherein L1 is a chemical bond, -CH2-, -CH2CH2-, -C(O)-, -CH2O-, -CH2O-CH2CH2O- or -NHC(O)-(CH2NHC(O)) a -;

[0290] L2 is a chemical bond or -CH2CH2C(O)-;

[0291] L3 is a chemical bond, -(NHCH2CH2) b -、-(NHCH2CH2CH2) b - or -C(O)CH2-;

[0292] L4 is -(OCH2CH2) c -、-(OCH2CH2CH2) c -、-(OCH2CH2CH2CH2) c -、- (OCH2CH2CH2CH2CH2CH2) c -or-NHC(O)-(CH2) d -;

[0293] Where a = 0, 1, 2 or 3;

[0294] b = 1, 2, 3, 4, or 5;

[0295] c = 1, 2, 3, 4, or 5;

[0296] d = 1, 2, 3, 4, 5, 6, 7, or 8;

[0297] L is -CH2O- or -NHC(O)-;

[0298] L' is a chemical bond, -C(O)NH- or -NHC(O)-;

[0299] R1 and R2 together form -CH2CH2O- or -CH2CH(R)-O-, and R3 is H;

[0300] Or R1 and R3 together form -C 1-2 Alkylene-, and R2 is H;

[0301] wherein R is -OR', -CH2OR' or -CH2CH2OR', wherein R' is H, a hydroxyl protecting group or a solid phase support, and the hydroxyl protecting group is preferably -C(O)CH2CH2C(O)OH or 4,4'-dimethoxytrityl;

[0302] m = 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;

[0303] n=0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.

[0304] In some specific embodiments, wherein,

[0305] Q is independently H or

[0306] Where L1 is -CH2O- or -NHC(O)-(CH2NHC(O)) a -;

[0307] L2 is -CH2CH2C(O)-;

[0308] L3 is -(NHCH2CH2) b -or-(NHCH2CH2CH2) b -;

[0309] L4 is -(OCH2CH2) c -or-NHC(O)-(CH2) d -;

[0310] Where a = 0, 1, 2 or 3;

[0311] b = 1, 2, 3, 4, or 5;

[0312] c = 1, 2, 3, 4, or 5;

[0313] d = 1, 2, 3, 4, 5, 6, 7, or 8;

[0314] L is -CH2O-;

[0315] L' is a chemical bond;

[0316] R1 and R2 together form -CH2CH2O- or -CH2CH(R)-O-, and R3 is H;

[0317] Or R1 and R3 together form -C 1-2 Alkylene-, and R2 is H;

[0318] wherein R is -OR', -CH2OR' or -CH2CH2OR', wherein R' is H, a hydroxyl protecting group or a solid phase support, and the hydroxyl protecting group is preferably -C(O)CH2CH2C(O)OH or 4,4'-dimethoxytrityl;

[0319] m = 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;

[0320] n=0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.

[0321] In some embodiments, the conjugated group is represented by Formula (I'-1), Formula (I'-2), or Formula (I'-3):

[0322] in,

[0323] Indicates the position where it is linked to the dsRNA;

[0324] Q is

[0325] Wherein L1 is -CH2O- or -NHC(O)-;

[0326] L2 is -CH2CH2C(O)-;

[0327] L3 is -(NHCH2CH2) b -or-(NHCH2CH2CH2) b -;

[0328] L4 is -(OCH2CH2) c -or-NHC(O)-(CH2) d -;

[0329] Where b = 1, 2, 3, 4 or 5;

[0330] c = 1, 2, 3, 4, or 5;

[0331] d = 1, 2, 3, 4, 5, 6, 7, or 8;

[0332] L is -CH2O-;

[0333] R' is H, a hydroxyl protecting group or a solid phase support, wherein the hydroxyl protecting group is preferably -C(O)CH2CH2C(O)OH or 4,4'-dimethoxytrityl;

[0334] n=0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.

[0335] In some specific embodiments, wherein,

[0336] Q is independently H,

[0337] Wherein L1 is -CH2O-, -CH2O-CH2CH2O- or -NHC(O)-(CH2NHC(O)) a -;

[0338] L2 is -CH2CH2C(O)-;

[0339] L3 is -(NHCH2CH2) b -、-(NHCH2CH2CH2) b - or -C(O)CH2-;

[0340] L4 is -(OCH2CH2) c -or-NHC(O)-(CH2) d -;

[0341] Where a = 0, 1, 2 or 3;

[0342] b = 1, 2, 3, 4, or 5;

[0343] c = 1, 2, 3, 4, or 5;

[0344] d = 1, 2, 3, 4, 5, 6, 7, or 8;

[0345] L is -CH2O- or -NHC(O)-;

[0346] L' is a chemical bond or -C(O)NH-;

[0347] R1 and R2 together form -CH2CH2O- or -CH2CH(R)-O-, and R3 is H;

[0348] Or R1 and R3 together form -C 1-2 Alkylene-, and R2 is H;

[0349] wherein R is -OR', -CH2OR' or -CH2CH2OR', wherein R' is H, a hydroxyl protecting group or a solid phase support, and the hydroxyl protecting group is preferably -C(O)CH2CH2C(O)OH or 4,4'-dimethoxytrityl;

[0350] m = 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;

[0351] n=0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.

[0352] In some embodiments, the conjugated group is as shown in Formula (II'-1) or Formula (II'-2):

[0353] in,

[0354] Indicates the position where it is linked to the dsRNA;

[0355] Q is independently

[0356] Wherein L1 is -CH2O- or -CH2O-CH2CH2O-;

[0357] L3 is -(NHCH2CH2) b -、-(NHCH2CH2CH2) b - or -C(O)CH2-;

[0358] L4 is -(OCH2CH2) c -or-NHC(O)-(CH2) d -;

[0359] Where b = 1, 2, 3, 4 or 5;

[0360] c = 1, 2, 3, 4, or 5;

[0361] d = 1, 2, 3, 4, 5, 6, 7, or 8;

[0362] L is -NHC(O)-;

[0363] L' is a chemical bond or -C(O)NH-;

[0364] R' is H, a hydroxyl protecting group or a solid phase support, wherein the hydroxyl protecting group is preferably -C(O)CH2CH2C(O)OH or 4,4'-dimethoxytrityl;

[0365] m = 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;

[0366] n=0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.

[0367] In some specific embodiments, wherein,

[0368] Q is independently H,

[0369] Wherein L1 is -CH2-, -C(O)-, -CH2O-, -CH2O-CH2CH2O- or -NHC(O)-(CH2NHC(O)) a -;

[0370] L2 is a chemical bond;

[0371] L3 is -(NHCH2CH2) b -、-(NHCH2CH2CH2) b - or -C(O)CH2-;

[0372] L4 is -(OCH2CH2) c -or-NHC(O)-(CH2)d -;

[0373] Where a = 0, 1, 2 or 3;

[0374] b = 1, 2, 3, 4, or 5;

[0375] c = 1, 2, 3, 4, or 5;

[0376] d = 1, 2, 3, 4, 5, 6, 7, or 8;

[0377] L is -CH2O- or -NHC(O)-;

[0378] L' is a chemical bond or -C(O)NH-;

[0379] R1 and R2 together form -CH2CH2O- or -CH2CH(R)-O-, and R3 is H;

[0380] Or R1 and R3 together form -C 1-2 Alkylene-, and R2 is H;

[0381] wherein R is -OR', -CH2OR' or -CH2CH2OR', wherein R' is H, a hydroxyl protecting group or a solid phase support, and the hydroxyl protecting group is preferably -C(O)CH2CH2C(O)OH or 4,4'-dimethoxytrityl;

[0382] m = 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;

[0383] n=0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.

[0384] In some embodiments, the conjugated group is represented by formula (II'-2):

[0385] in,

[0386] Indicates the position where it is linked to the dsRNA;

[0387] Q is independently

[0388] Wherein L1 is -CH2- or -C(O)-;

[0389] L3 is -(NHCH2CH2) b -;

[0390] L4 is -(OCH2CH2) c -;

[0391] Where b = 1, 2, 3, 4 or 5;

[0392] c = 1, 2, 3, 4, or 5;

[0393] L is -CH2O- or -NHC(O)-;

[0394] R' is H, a hydroxyl protecting group or a solid phase support, wherein the hydroxyl protecting group is preferably -C(O)CH2CH2C(O)OH or 4,4'-dimethoxytrityl;

[0395] n=0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.

[0396] In some specific embodiments, wherein:

[0397] Q is independently H,

[0398] Wherein L1 is a chemical bond, -CH2-, -CH2CH2-, -C(O)-, -CH2O-, -CH2O-CH2CH2O- or -NHC(O)-(CH2NHC(O)) a -;

[0399] L2 is a chemical bond or -CH2CH2C(O)-;

[0400] L3 is a chemical bond, -(NHCH2CH2) b -、-(NHCH2CH2CH2) b - or -C(O)CH2-;

[0401] L4 is -(OCH2CH2) c -、-(OCH2CH2CH2) c -、-(OCH2CH2CH2CH2) c -、-(OCH2CH2CH2CH2CH2) c -or-NHC(O)-(CH2) d -;

[0402] Where a = 0, 1, 2 or 3;

[0403] b = 1, 2, 3, 4, or 5;

[0404] c = 1, 2, 3, 4, or 5;

[0405] d = 1, 2, 3, 4, 5, 6, 7, or 8;

[0406] L is a chemical bond, -CH2O- or -NHC(O)-;

[0407] L' is a chemical bond, -C(O)NH-, -NHC(O)- or -O(CH2CH2O) e -;

[0408] Where e is 1, 2, 3, 4 or 5;

[0409] T is a chemical bond, -CH2-, -M-, -CH2-M- or -C(O)-M-;

[0410] Where M is

[0411] R1 and R2 together form -CH2CH2O- or -CH2CH(R)-O-, and R3 is H;

[0412] Or R1 and R3 together form -C 1-2 Alkylene-, and R2 is H;

[0413] wherein R is -OR', -CH2OR' or -CH2CH2OR', wherein R' is H, a hydroxyl protecting group or a solid phase support, and the hydroxyl protecting group is preferably -C(O)CH2CH2C(O)OH or 4,4'-dimethoxytrityl;

[0414] m = 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;

[0415] n=0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.

[0416] In some specific embodiments, wherein,

[0417] T is -M-, -CH2-M- or -C(O)-M-, wherein M is

[0418] In some specific embodiments, wherein,

[0419] Q is independently H or

[0420] Where L1 is -CH2O- or -NHC(O)-(CH2NHC(O)) a -;

[0421] L2 is -CH2CH2C(O)-;

[0422] L3 is -(NHCH2CH2) b -or-(NHCH2CH2CH2) b -;

[0423] L4 is -(OCH2CH2) c-or-NHC(O)-(CH2) d -;

[0424] Where a = 0, 1, 2 or 3;

[0425] b = 1, 2, 3, 4, or 5;

[0426] c = 1, 2, 3, 4, or 5;

[0427] d = 1, 2, 3, 4, 5, 6, 7, or 8;

[0428] L is a chemical bond or -CH2O-;

[0429] L' is a chemical bond or -O(CH2CH2O) e -;

[0430] Where e is 1, 2, 3, 4 or 5;

[0431] R1 and R2 together form -CH2CH2O- or -CH2CH(R)-O-, and R3 is H;

[0432] Or R1 and R3 together form -C 1-2 Alkylene-, and R2 is H;

[0433] wherein R is -OR', -CH2OR' or -CH2CH2OR', wherein R' is H, a hydroxyl protecting group or a solid phase support, and the hydroxyl protecting group is preferably -C(O)CH2CH2C(O)OH or 4,4'-dimethoxytrityl;

[0434] m = 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;

[0435] n=0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;

[0436] wherein T is as defined in the above embodiment.

[0437] In some embodiments, the conjugated group is represented by Formula (III'-1), Formula (III'-2), or Formula (III'-3):

[0438] in,

[0439] Q is

[0440] Wherein L1 is -CH2O- or -NHC(O)-;

[0441] L2 is -CH2CH2C(O)-;

[0442] L3 is -(NHCH2CH2)b -or-(NHCH2CH2CH2) b -;

[0443] L4 is -(OCH2CH2) c -or-NHC(O)-(CH2) d -;

[0444] Where b = 1, 2, 3, 4 or 5;

[0445] c = 1, 2, 3, 4, or 5;

[0446] d = 1, 2, 3, 4, 5, 6, 7, or 8;

[0447] L is a chemical bond or -CH2O-;

[0448] Wherein R' is H, a hydroxyl protecting group or a solid phase support, and the hydroxyl protecting group is preferably -C(O)CH2CH2C(O)OH or 4,4'-dimethoxytrityl;

[0449] n=0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;

[0450] wherein T is as defined in the above embodiment.

[0451] In some specific embodiments, wherein,

[0452] Q is independently H,

[0453] Wherein L1 is -CH2-, -CH2O- or -C(O)-;

[0454] L2 is a chemical bond;

[0455] L3 is -(NHCH2CH2) b -、-(NHCH2CH2CH2) b - or -C(O)CH2-;

[0456] L4 is -(OCH2CH2) c -or-NHC(O)-(CH2) d -;

[0457] Where b = 1, 2, 3, 4 or 5;

[0458] c = 1, 2, 3, 4, or 5;

[0459] d = 1, 2, 3, 4, 5, 6, 7, or 8;

[0460] L is a chemical bond or -NHC(O)-;

[0461] L' is a chemical bond;

[0462] R1 and R2 together form -CH2CH2O- or -CH2CH(R)-O-, and R3 is H;

[0463] Or R1 and R3 together form -C 1-2 Alkylene-, and R2 is H;

[0464] wherein R is -OR', -CH2OR' or -CH2CH2OR', wherein R' is H, a hydroxyl protecting group or a solid phase support, and the hydroxyl protecting group is preferably -C(O)CH2CH2C(O)OH or 4,4'-dimethoxytrityl;

[0465] m = 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;

[0466] n=0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;

[0467] wherein T is as defined in the above embodiment.

[0468] In some embodiments, the conjugated group is represented by formula (IV-1) or formula (IV-2):

[0469] in,

[0470] Q is independently

[0471] Wherein L1 is -CH2-, -CH2O- or -C(O)-;

[0472] L3 is -(NHCH2CH2) b -、-(NHCH2CH2CH2) b - or -C(O)CH2-;

[0473] L4 is -(OCH2CH2) c -or-NHC(O)-(CH2) d -;

[0474] Where b = 1, 2, 3, 4 or 5;

[0475] c = 1, 2, 3, 4, or 5;

[0476] d = 1, 2, 3, 4, 5, 6, 7, or 8;

[0477] L is a chemical bond or -NHC(O)-;

[0478] L' is a chemical bond;

[0479] Wherein R' is H, a hydroxyl protecting group or a solid phase support, and the hydroxyl protecting group is preferably -C(O)CH2CH2C(O)OH or 4,4'-dimethoxytrityl;

[0480] m = 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;

[0481] n=0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;

[0482] wherein T is as defined in the above embodiment.

[0483] In some specific embodiments, wherein:

[0484] Q is independently H,

[0485] Wherein L1 is a chemical bond, -CH2-, -CH2CH2-, -C(O)-, -CH2O-, -CH2O-CH2CH2O- or -NHC(O)-(CH2NHC(O)) a -;

[0486] L2 is a chemical bond or -CH2CH2C(O)-;

[0487] L3 is a chemical bond, -(NHCH2CH2) b -、-(NHCH2CH2CH2) b - or -C(O)CH2-;

[0488] L4 is -(OCH2CH2) c -、-(OCH2CH2CH2) c -、-(OCH2CH2CH2CH2) c -、-(OCH2CH2CH2CH2CH2) c -or-NHC(O)-(CH2) d -;

[0489] Where a = 0, 1, 2 or 3;

[0490] b = 1, 2, 3, 4, or 5;

[0491] c = 1, 2, 3, 4, or 5;

[0492] d = 1, 2, 3, 4, 5, 6, 7, or 8;

[0493] L is a chemical bond, -CH2O- or -NHC(O)-;

[0494] L' is -O(CH2CH2O)e -;

[0495] Where e is 1, 2, 3, 4 or 5;

[0496] T is a chemical bond, -CH2-, -C(O)-, -M-, -CH2-M- or -C(O)-M-;

[0497] Where M is

[0498] R1 and R2 together form -CH2CH2O- or -CH2CH(R)-O-, and R3 is H;

[0499] Or R1 and R3 together form -C 1-2 Alkylene-, and R2 is H;

[0500] wherein R is -OR', -CH2OR' or -CH2CH2OR', wherein R' is H, a hydroxyl protecting group or a solid phase support, and the hydroxyl protecting group is preferably -C(O)CH2CH2C(O)OH or 4,4'-dimethoxytrityl;

[0501] m = 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;

[0502] n=0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.

[0503] In some preferred embodiments, the conjugated group is selected from the following Table 1:

[0504] Table 1

[0505] In some preferred embodiments, the conjugated group is selected from the following Table 2:

[0506] Table 2

[0507] In some embodiments, the ligand targets the asialoglycoprotein receptor (ASGPR).In some embodiments, the ligand targets the asialoglycoprotein receptor (ASGPR) on hepatocytes.

[0508] In some embodiments, the ligand has the following structure:

[0509] in Indicates the position of attachment to the dsRNA via a phosphate group or a phosphorothioate group.

[0510] In some embodiments, the ligand has the following structure:

[0511] in Indicates the position of attachment to the dsRNA via a phosphate group or a phosphorothioate group.

[0512] In some embodiments, the ligand has the following structure:

[0513] in Indicates the position of linkage to the sense strand of the dsRNA via a phosphate group or a phosphorothioate group.

[0514] In some embodiments, the ligand has the following structure:

[0515] in Indicates the position of linkage to the sense strand of the dsRNA via a phosphate group or a phosphorothioate group.

[0516] In some embodiments, the sense strand comprises a sense strand sequence selected from any one of SEQ ID NOs: 60-79. In some preferred embodiments, the dsRNA comprises a sense strand sequence and an antisense strand sequence selected from any one of the pairs shown in Table 7.

[0517] IV. Inhibition of AGT gene expression

[0518] The dsRNA of the invention is capable of inhibiting AGT gene expression by at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%.

[0519] Inhibition of AGT gene expression can be manifested by a decrease in the amount of mRNA expressed by a first cell or group of cells (such cells can be present, for example, in a sample derived from a subject) in which the AGT gene is transcribed and which cell or cells have been treated (for example, by contacting the cell or cells with a dsRNA of the invention, or by administering a dsRNA of the invention to a subject in which the cells are or were present) such that AGT gene expression is inhibited compared to a second cell or group of cells (one or more control cells) that is substantially identical to the first cell or group of cells but has not been so treated.

[0520] In preferred embodiments, inhibition is assessed by expressing the level of mRNA in treated cells as a percentage of the level of mRNA in control cells using the formula: -△△Ct The difference between the experimental group and the control group was compared by ΔΔCt, where ΔΔCt = [(Ct target gene of experimental group - Ct internal reference of experimental group) - (Ct target gene of control group - Ct internal reference of control group)].

[0521] Alternatively, the inhibition of AGT gene expression, for example AGT protein expression, can be assessed with respect to the reduction of parameters functionally related to AGT gene expression (such as lipid levels, cholesterol levels, for example LDLc levels). AGT gene silencing can be determined in any cell expressing AGT constitutively or by genome engineering and by any assay known in the art. The liver and kidney are the main sites of AGT expression, and other important expression sites include the small intestine, white adipose tissue, and colon.

[0522] Inhibition of AGT protein expression can be demonstrated by a decrease in the level of AGT protein expressed by a cell or cell group (e.g., the level of protein expressed in a sample derived from a subject). As explained above with respect to the assessment of mRNA inhibition, inhibition of protein expression levels in treated cells or cell groups can similarly be expressed as a percentage of the level of protein in control cells or cell groups.

[0523] Control cells or cell groups that can be used to assess inhibition of AGT gene expression include cells or cell groups that have not been contacted with the dsRNA of the invention. For example, the control cells or cell groups can be derived from an individual subject (e.g., a human or animal subject) before the subject is treated with the dsRNA.

[0524] V. Vector

[0525] The present invention provides a vector comprising a nucleotide sequence encoding the dsRNA of the present invention. The vector of the present invention is capable of amplifying and / or expressing the nucleotide sequence encoding the dsRNA of the present invention to which it is attached. The vector of the present invention can be a virus, a plasmid, or a cosmid.

[0526] dsRNA targeting the AGT gene can be expressed from a transcription unit inserted into a DNA or RNA vector. Expression can be transient (within hours to weeks) or sustained (weeks to months or longer), depending on the specific construct used and the type of target tissue or cell. The nucleotides encoding the dsRNA targeting the AGT mRNA can be introduced into a linear construct, a circular plasmid, or a viral vector. The nucleotides encoding the dsRNA targeting the AGT mRNA can be integrated into the cell genome for stable expression, or stably inherited and expressed extrachromosomally. In general, dsRNA expression vectors are typically DNA plasmids or viral vectors. Viral vector systems containing the coding sequence of the dsRNA targeting the AGT mRNA include, but are not limited to: (a) adenoviral vectors; (b) retroviral vectors; (c) adeno-associated viral vectors; (d) herpes simplex virus vectors; (e) SV40 vectors; (f) polyoma virus vectors; (g) papilloma virus vectors; (h) picornavirus vectors; or (i) poxvirus vectors.

[0527] VI. Cells

[0528] The present invention provides a cell comprising the dsRNA or vector of the present invention.

[0529] VII. Pharmaceutical Compositions

[0530] The present invention provides a pharmaceutical composition comprising the dsRNA, vector or cell of the present invention, and optionally a pharmaceutically acceptable carrier or excipient.

[0531] As used herein, "pharmaceutically acceptable" refers to those compounds, materials, compositions, and / or dosage forms which, within the scope of sound medical judgment, are suitable for use in contact with the tissues of human and animal subjects without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio.

[0532] As used herein, a pharmaceutically acceptable carrier refers to a pharmaceutical carrier that facilitates administration of dsRNA or vectors or cells containing its coding sequence into the human body and / or facilitates its absorption or function. Examples include diluents and excipients such as water; fillers such as starch and sucrose; binders such as cellulose derivatives, alginates, gelatin, and polyvinyl pyrrolidone; humectants such as glycerol; disintegrants such as agar, calcium carbonate, and sodium bicarbonate; absorption enhancers such as quaternary ammonium compounds; surfactants such as cetyl alcohol; adsorption carriers such as kaolin and bentonite; and lubricants such as talc, calcium / magnesium stearate, and polyethylene glycol. Other adjuvants such as flavoring agents and sweeteners may also be added to the composition.

[0533] The pharmaceutical composition of the present invention may comprise a pharmaceutically acceptable diluent or a sustained-release matrix, in which the dsRNA or vector of the present invention is embedded.

[0534] Pharmaceutical composition of the present invention can comprise the drug delivery system for sending dsRNA.Drug delivery system of the present invention includes but is not limited to nano-particle (such as lipid nano-particle, nano-particle based on polymer), polymer, PEG or cationic delivery system, polylactic acid (PLA) microsphere, poly(lactic-co-glycolic acid) (PLGA) microsphere, liposome, micelle, reverse micelle (inverse micelles), lipid spiral (lipid cochleates) or lipid microtubule (lipid microtubules).Cholesterol, PEG lipid PEG-2000-C-DMG, PEG-2000-DMG (Moderna), ALC-0159 and DSPC.

[0535] In some embodiments, the siRNA or carrier in the pharmaceutical compositions of the present invention may be contained in polymers and polymer-based nanoparticles.

[0536] In some specific embodiments, the polymer is a poly(lactic-co-glycolic acid) (PLGA)-based polymer. In some specific embodiments, the PLGA-based polymer is modified to contain a single cationic group.

[0537] In some specific embodiments, the polymer contains an amine group that can become cationic, such as polyethyleneimine (PEI) and poly (L-lysine) (PLL), which can form a complex with siRNA through electrostatic interactions and deliver siRNA into cells. In some embodiments, PEG and PLL are chemically modified to improve in vivo efficacy and tolerability.

[0538] In some embodiments, the siRNA, vector, or cells in the pharmaceutical compositions of the present invention can be delivered via the cationic polymer poly(β-amino ester) (PBAE).

[0539] VIII. Kit

[0540] The present invention provides a kit comprising the dsRNA, vector or cell of the present invention.

[0541] The present invention also provides kits for using the dsRNAs described herein and / or performing the methods described herein. Such kits include one or more dsRNAs, vectors, or cells described herein, and may further include instructions for use. The instructions may include instructions for inhibiting AGT expression in cells by contacting the cells with the dsRNA or vector described herein in an amount effective to inhibit AGT expression.

[0542] When the dsRNA or vector of the present invention is contacted with cells in vitro, the kit of the present invention may optionally further comprise a means for contacting cells with the dsRNA or vector of the present invention (e.g., an injection device) or a means for measuring the inhibitory effect of AGT (e.g., a device for measuring the inhibition of AGT mRNA or protein). Such a device for measuring the inhibition of AGT may comprise a device for obtaining a sample (e.g., a plasma sample) from a subject.

[0543] When the dsRNA, vector, or cells into which the dsRNA or vector has been introduced in vitro of the present invention are administered in vivo, the kit of the present invention may optionally further comprise a device for administering the dsRNA, vector, or cells of the present invention to a subject, or a device for determining a therapeutically effective amount or a prophylactically effective amount.

[0544] IX. Methods of treatment and pharmaceutical uses

[0545] The present invention provides a method for reducing angiotensinogen (AGT) in a subject, comprising the step of administering to the subject the dsRNA, vector, cell, or pharmaceutical composition of the present invention.

[0546] The present invention provides a method for treating, preventing, inhibiting or alleviating a disease or condition that benefits from reduced angiotensinogen (AGT) expression in a subject, the method comprising administering to the subject a dsRNA, vector, cell, or pharmaceutical composition of the present invention. The present invention also provides a method for treating, preventing, inhibiting or alleviating at least one symptom in a patient suffering from a disease or condition that benefits from reduced angiotensinogen (AGT) expression.

[0547] In some embodiments, the disease or condition that would benefit from reduced expression of angiotensinogen (AGT) is an AGT-related disease.

[0548] In some embodiments, the invention provides a method of reducing angiotensinogen (AGT) in a subject, a method of treating, preventing, inhibiting or alleviating a disease or condition that benefits from reduced angiotensinogen (AGT) expression in a subject, or a method of treating, preventing, inhibiting or alleviating at least one symptom in a patient suffering from a disease or condition that benefits from reduced angiotensinogen (AGT) expression, comprising administering the dsRNA, vector, cell or pharmaceutical composition subcutaneously, topically, or intravenously to the subject. In some embodiments, the subject is a human patient.

[0549] The present invention also relates to the dsRNA, vector, cell or pharmaceutical composition of the present invention for use in treating a disease or symptom associated with AGT expression in a subject.

[0550] The present invention also relates to the use of the dsRNA, vector, cell, or pharmaceutical composition of the present invention in the preparation of a medicament for treating, preventing, inhibiting, or alleviating a disease or condition that would benefit from reduced angiotensinogen (AGT) expression in a subject. The present invention also relates to the use of the dsRNA, vector, cell, or pharmaceutical composition of the present invention in the preparation of a medicament for reducing angiotensinogen (AGT) in a subject. The present invention also relates to the use of the dsRNA, vector, cell, or pharmaceutical composition of the present invention in the preparation of a medicament for treating, preventing, inhibiting, or alleviating at least one symptom in a patient suffering from a disease or condition that would benefit from reduced angiotensinogen (AGT) expression.

[0551] sequence

[0552] The RNA sequence provided by the present invention targets the human AGT gene (or target gene, target mRNA sequence, target sequence). The target AGT mRNA sequence is the gene shown in Genbank accession number NM_001393338.1.

[0553] Table 3. Nucleotide sequences of the sense and antisense strands targeting AGT mRNA

[0554] Table 4 and Table 5 respectively show the modified RNA sequences used in the present invention.

[0555] In this article, the meanings of the abbreviations are as follows:

[0556] The A, U, G, and C distribution represents the natural adenine, uracil, guanine, and cytosine ribonucleotides.

[0557] d indicates that the nucleotide adjacent to its right is a deoxyribonucleotide. For example, dA, dT, dG, and dC represent adenine deoxyribonucleotide, thymine deoxyribonucleotide, guanine deoxyribonucleotide, and cytosine deoxyribonucleotide, respectively.

[0558] m indicates that the nucleotide adjacent to its left is a 2'-OCH3-modified nucleotide. For example, Am, Um, Gm, and Cm represent 2'-OCH3-modified A, U, G, and C, respectively.

[0559] f indicates that the nucleotide adjacent to its left is a 2'-fluoro-modified nucleotide. For example, Af, Uf, Gf, and Cf represent 2'-fluoro-modified A, U, G, and C, respectively.

[0560] "s" indicates that the two adjacent nucleotides on the left and right are linked by phosphorothioate.

[0561] "s-" indicates that the adjacent nucleotide on its left side is linked to the adjacent delivery vector on its right side through a phosphorothioate linkage.

[0562] VP indicates that the adjacent nucleotide on its right is a vinyl phosphate-modified nucleotide, which is well known in the art, and can be found in, for example, PCT Publication Nos. WO2011139702, WO2013033230, and WO2019105419.

[0563] Tgn and Agn are adenosine-glycol nucleic acid (GNA) S-isomer and thymidine-glycol nucleic acid (GNA) S-isomer, respectively, and are well known in the art. For example, see PCT Publication Nos. WO2019222166A1 and WO2020132227A2. Their structures are

[0564] wherein B is thymine (for thymidine-glycol nucleic acid (GNA) S-isomer) or adenine (for adenosine-glycol nucleic acid (GNA) S-isomer).

[0565] IB represents an inverted abasic deoxyribonucleotide, which can include the following three structures depending on its position / linkage in dsRNA. IB is well known in the art, see, for example, F. Czauderna, Nucleic Acids Res., 2003, 31(11), 2705-16 and PCT Publication Nos. WO2016011123 and WO2019051402.

[0566] L96 represents a GalNAc delivery vector of the following structure well known in the art, wherein Refers to positions linked to the dsRNA via a phosphate group or a phosphorothioate group, see, for example, PCT Publication Nos. WO2009073809 and WO2009082607.

[0567] GL6 represents a GalNAc delivery vector of the following structure, wherein Indicates the position where the dsRNA is linked via a phosphate or phosphorothioate group

[0568] "SCP modified nucleotide" refers to a modified nucleotide having the following structure: Wherein Base is independently selected from H, a modified or unmodified base or a leaving group. Preferably, Base is an unmodified base, including adenine base, guanine base, uracil base and cytosine base. For example, SCP-U indicates that Base is a uracil base.

[0569] Table 4. Modified siRNA sense strand sequences targeting AGT mRNA

[0570] Table 5. Modified siRNA antisense strand sequences targeting AGT mRNA

[0571] SR008688S in Table 4 and SR011274A in Table 5 are both control sequences.

[0572] Table 6. Paired siRNA sense and antisense strands targeting AGT mRNA

[0573] Table 7. Paired siRNA sense and antisense strands targeting AGT mRNA

[0574] The present invention will be further described below with reference to the following examples. It should be understood that the following examples are merely illustrative and should not be considered as limiting the scope of the present invention. Example

[0575] Unless otherwise specified, the sources of materials used in the examples are as follows:

[0576] Huh7 cell line was purchased from Nanjing Kebai, catalog number CBP60202

[0577] Hep3B cell line was purchased from Nanjing Kebai, catalog number CBP60197

[0578] PHH cells were purchased from Shanghai Xuanyi, product number QYLF-HPMC

[0579] HEK293A cell line was purchased from Nanjing Kebai, catalog number CBP60436

[0580] Balb / c mice were obtained from Zhejiang Weitong Lihua, catalog number Balb / c

[0581] Example 1 Preparation of Compound E7

[0582] 1. Preparation of Intermediates 3-4

[0583] 1.1 Preparation of Compound 2

[0584] To compound 1 (300 g, 2.01 mol) in DCM (1.80 L) was slowly added benzyl (2,5-dioxopyrrolidin-1-yl) carbonate (600 g, 2.40 mol) at 15°C and TEA (203 g, 2.01 mol, 280 mL) was added dropwise. After the addition, the mixture was stirred at 25°C for 16 hours. TLC (dichloromethane:methanol = 10:1) showed that reactant 1 (R f =0.32) is retained and an important new point is detected (R f =0.52). The reaction mixture was washed with saturated sodium bicarbonate solution (1.00 L x 2), and the organic phase was washed with brine (1.00 L), dried over anhydrous Na2SO4 and concentrated in vacuo. Without purification, compound 2 (about 385 g) was obtained as a yellow oil.

[0585] 1.2 Preparation of compound 2A

[0586] At 0-15 ℃, DMAP (19.8g, 162mmol) was added to a pyridine (1.75L) solution of compound 4 (350g, 1.62mol, HCl) and Ac2O (994g, 9.74mol, 912mL) at a disposable rate and TEA (164g, 1.62mol, 226mL) was added dropwise. The mixture was stirred at 25 ℃ for 16 hours. LCMS (product: RT=0.687min) showed that the starting reactants were completely consumed. EtOAc (1.40L) was added to the mixture at 25 ℃ and stirred for 30 minutes, then the mixture was filtered and the filter cake was washed with EtOAc (300mL). The filter cake was ground with water (1.45L) for 30 minutes at 25 ℃. The mixture was filtered and the filter cake was washed with water (175mL x 3), and the filter cake was collected to obtain compound 2A (about 580g) as a white solid.

[0587] 1.3 Preparation of compound 2B

[0588] Three reactions were performed in parallel.

[0589] To a solution of compound 2A (200 g, 514 mmol) in DCM (800 mL) was added TMSOTf (137 g, 616 mmol, 111 mL) dropwise at 10-15° C. over 0.5 h. The mixture was then stirred at 25° C. for 3 h. TLC (dichloromethane:methanol=20:1) showed that compound 2A (R f =0.54) is completely consumed and the new point (R f =0.24) was formed. The three reactions were combined. The mixture was cooled to 0-15°C and slowly poured into a solution of NaHCO3 (300 g dissolved in 3.00 L water) at 0-5°C. The organic phase was separated and the aqueous phase was extracted with DCM (1.00 L x 3). The organic layers were combined, dried over Na2SO4, filtered and concentrated in vacuo. Without purification, compound 2B (approximately 507 g) was obtained as a yellow oil and used in the next step.

[0590] 1.4 Preparation of compound 3

[0591] To a mixture of compound 2B (250 g, 759 mmol) and compound 2 (151 g, 531 mmol) in DCM (1.00 L) was added TMSOTf (84.4 g, 380 mmol, 69.0 mL) dropwise at 0-10° C. and the mixture was stirred at 20° C. for 12 hours. TLC (dichloromethane:methanol=20:1) showed that compound 2 (R f =0.33) is completely consumed and a new point is formed (R f =0.03). The combined reaction was cooled to 0-5°C and then poured into NaHCO (aqueous solution, 100 g dissolved in 1 L of water) and stirred at 5-10°C for 10 minutes. The phases were separated. The aqueous phase was extracted with DCM (500 mL x 2), the combined organic phases were dried over NaSO, filtered, and the filtrate was concentrated in vacuo. Without purification, compound 3 (approximately 360 g) was obtained as a yellow oil.

[0592] 1 H NMR: (400 MHz, DMSO).

[0593] δ=7.79-7.37(m,1H),7.35-7.26(m,5H),5.21-5.20(m,1H),5.00-4.95(m,3H),4.55-4.53(m,1H),4.03-3.86(m,3H),3.61-3.59(m,1H) ,3.59-3.57(m,1H),3.48-3.40(m,6H),3.39-3.31(m,2H),3.14-3.13(m,2H),2.09(s,3H),1.99(s,3H),1.88(s,3H),1.76-1.74(m,3H).

[0594] 1.5 Preparation of Intermediate 3-4 (TFA Salt)

[0595] Three reactions were performed in parallel.

[0596] To a mixture of Pd / C (18.0 g, 16.3 mmol, 10% content) in THF (1.80 L) was added compound 3 (180 g, 293 mmol) and TFA (33.5 g, 293 mmol, 21.8 mL) under an argon atmosphere. The suspension was vented and vented three times with hydrogen. The mixture was stirred at H2 (50 Psi) and 30 ° C for 2 hours. LCMS (product: RT = 0.697 min) showed that compound 3 was consumed and a product peak was detected. The three reactions were combined. The mixture was filtered through celite and the filtrate was concentrated under reduced pressure to remove the solvent. Intermediate 3-4 (TFA salt) (393 g, 660 mmol, 74.8% yield, 99.6% purity, TFA) was obtained as a yellow solid without purification.

[0597] 1 H NMR: (400 MHz, DMSO-d6)

[0598] δ=7.92(d,J=9.1Hz,4H),5.27-5.17(m,1H),5.03-4.91(m,1H),4.60-4.50(m,1H),4.09-3.97(m,4H),3.85(s ,2H),3.65-3.46(m,10H),3.04-2.92(m,2H),2.10(s,3H),2.00(s,3H),1.94-1.86(m,3H),1.82-1.71(m,4H).

[0599] 2. Preparation of Intermediate 3-3

[0600] 2.1 Preparation of compound 5

[0601] To a solution of compound 4B (10.0 g, 35.5 mmol, 1.00 eq) and compound 3-4 (46.3 g, 78.2 mmol, 2.20 eq, TFA) prepared above in DCM (1.00 L) was added DIEA (30.3 g, 234 mmol, 40.8 mL, 6.60 eq) in one portion at 25°C. The mixture was stirred for half an hour at 25°C. HBTU (30.3 g, 234 mmol, 40.8 mL, 6.60 eq) was added to the mixture. The mixture was stirred at 25°C for 16 hours. LCMS (product: RT = 0.681 mins) indicated the reaction was complete, and the mixture was concentrated in vacuo. At 20 ℃, 0.50N HCl (200mL x 2) was added to the mixture, and extracted with DCM (3x 500mL), the combined organic layers were washed with saturated NaHCO (3x 800mL) until pH=8, washed with brine (3x 500mL), and dried and concentrated in vacuo to purify. The residue was purified by column chromatography (SiO , DCM:MeOH=50:1-15:1). The residue was concentrated in vacuo at 40 ℃ and purified by preparative-MPLC (column: 800g Agela C18; mobile phase: [water-ACN]; 15-45% 25min; 45% 10min). Vacuum drying was used to obtain compound 5 (approximately 180g+75.0g+87.0g+40.0g+38.0g) as a yellow solid.

[0602] 417.0 g of compound 3-4 was converted into compound 5 through 9 batches.

[0603] 2.2 Preparation of intermediate 3-3

[0604] Compound 5 (73.0 g, 61.7 mmol, 1.00 eq) and TFA (7.04 g, 61.7 mmol, 4.57 mL, 1.00 eq) were added to a solution of Pd / C (3.00 g, 10% content) in THF (300 mL) under an argon atmosphere. The suspension was degassed and purged with hydrogen three times. The mixture was stirred at 20°C under H2 (20 Psi) for 16 hours. TLC (dichloromethane:methanol = 8:1, R f =0.0) indicated that the reaction was complete. The mixture was filtered through celite, and the filtrate was concentrated under pressure to remove the solvent to obtain compound 3-3 (about 33.4 g + 129 g + 75.0 g) as a white solid.

[0605] 1 H NMR: (400 MHz, DMSO)

[0606] δ=8.53(t,J=5.2Hz,1H),8.18(d,J=2.4Hz,3H),8.03(t,J=5.2Hz,1H),7.84(dd,J=3.6H z,2H),5.22(d,J=3.2Hz,2H),4.96(dd,J=3.2Hz,2H),4.55(d,J=8.4Hz,2H),4.02(t,J= 8.8Hz,6H),3.77-3.59(m,5H),3.58-3.45(m,21H),3.40-3.20(m,4H),2.18(t,J=7.6Hz ,2H),2.17(d,J=8.0Hz,6H),2.10(s,6H),1.99(s,6H),1.90-1.80(m,8H),1.77(s,6H).

[0607] 3. Preparation of Compound E7

[0608] 3.1 Preparation of compound 3

[0609] Compound 1 (2.00 g, 1.87 mmol, prepared according to the method for Intermediate 3-3 above) was dissolved in DCM (20.0 mL) at room temperature. DIEA (0.135 mL, 0.814 mmol) and compound 2 (0.550 g, 0.814 mmol) were added sequentially to the solution, and the nitrogen atmosphere was replaced three times. The reaction mixture was stirred at 25°C for 16 hours. LC-MS / MS detected the product's MS response, and thin-layer chromatography (dichloromethane / methanol = 5 / 1) showed the disappearance of the starting material and the formation of new spots. The reaction solution was concentrated under reduced pressure, and the resulting crude product was purified by column chromatography (dichloromethane / methanol = 5 / 1) to afford compound 3 (approximately 780 mg) as a white solid.

[0610] 1 H NMR (400 MHz, CD3OD)

[0611] δ=7.28-7.42(m,5H),5.30-5.34(m,4H),5.04-5.14(m,6H),4.63-4.67( m,4H),4.36-4.44(m,2H),4.00-4.20(m,23H),3.91-3.95(m,4H),3.69-3 .77(m,9H),3.52-3.67(m,32H),3.34-3.43(m,9H),2.29-2.31(m,4H),2. 14(s,12H),2.03(s,12H),1.92-1.96(m,24H).LCMS:m / z=1221.6(M / 2+H) + .

[0612] 3.2 Preparation of compound 4

[0613] Compound 3 (1.10 g, 0.451 mmol) was dissolved in MeOH (10.0 mL) at room temperature. 10% wet Pd / C (0.050 g, 0.451 mmol) was added to the solution. The hydrogen atmosphere was replaced three times, and the reaction mixture was stirred at 25°C for 18 hours under a hydrogen atmosphere (14.696 psi). Liquid chromatography-mass spectrometry (LC-MS / MS) detected the product. Thin-layer chromatography (dichloromethane / methanol = 10 / 1, phosphomolybdic acid) revealed complete consumption of the starting material and the formation of new spots. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure to yield compound 4 (approximately 840 mg) as a white solid.

[0614] 1 H NMR (400 MHz, CD3OD)

[0615] δ=5.32-5.34(m 4H),5.06-5.10(m,4H),4.63-4.65(m,4H),4.38-4.40(m,2H),3.99-4.20(m,20H),3.90-3.97(m,4H),3.69-3.76(m,6H),3.50-3 .68(m,36H),3.35-3.44(m,11H),2.28-2.38(m,4H),2.15(s,12H),2.03(s,12H),1.90-1.94(m,24H).LCMS:m / z=1154.7(M / 2+H) + .

[0616] 3.3 Preparation of compound 6

[0617] Compound 5 (232 mg, 0.364 mmol) was dissolved in DCM (10.0 mL) at room temperature. HBTU (207 mg, 0.546 mmol), DIEA (0.181 mL, 1.09 mmol), and compound 4 (840 mg, 0.364 mmol) were added sequentially to the solution, and the atmosphere was purged with nitrogen three times. The reaction mixture was stirred at 25°C for 1 hour. LC / MS analysis revealed the disappearance of the starting material, while thin-layer chromatography (dichloromethane / methanol = 5 / 1) showed the disappearance of the starting material and the formation of new spots. The reaction mixture was concentrated under reduced pressure, and the resulting crude product was purified by column chromatography (dichloromethane / methanol = 8 / 1 to 5 / 1) to afford compound 6 (approximately 620 mg) as a white solid.

[0618] 1 H NMR (400 MHz, CD3OD)

[0619] δ=7.41-7.43(m,2H),7.23-7.34(m,7H),6.83-6.90(m,4H),5.31-5.35(m,4H),5.01-5.12(m ,4H),4.63-4.65(m,4H),4.41-4.45(m,2H),4.31-4.33(m,1H),3.99-4.22(m,22H),3.87-3.9 7(m,6H),3.58-3.81(m,45H),3.34-3.43(m,10H),2.19-2.40(m,10H),2.14(s,12H),2.02(s ,12H),1.92-1.96(mz,24H),1.48-1.63(m,4H),1.28-1.38(m,8H).LCMS:m / z=1460.0(M / 2+H) + .

[0620] 4. Preparation of Compound E7

[0621] Compound 6 (300 mg, 0.103 mmol) was dissolved in DCM (10.0 mL) at room temperature. DIEA (0.102 mL, 0.618 mmol), compound 7 (10.3 mg, 0.103 mmol), and DMAP (12.6 mg, 0.103 mmol) were added sequentially to the solution, and the atmosphere was replaced with nitrogen three times. The reaction mixture was stirred at 25°C for 2 hours. LC / MS / MS analysis confirmed the disappearance of the starting material. The reaction solution was concentrated under reduced pressure, and the resulting crude product was separated by preparative HPLC (Preparative-HPLC, column: Waters Xbridge BEH C18 100*30 mm*10 μm; mobile phase: water-ACN; B%: 17%-57%, 5 min) to afford compound E7 (53.0 mg, yield 17.08%, purity 78.94%) as a white solid.

[0622] 1 H NMR (400 MHz, CD3OD)

[0623] δ=7.41-7.45(m,2H),7.17-7.34(m,7H),6.85-6.89(m,4H),5.32-5.36(m,4H),5.03-5.13(m,4H),4.63- 4.67(m,4H),4.38-4.47(m,2H),4.32-4.34(m,1H),4.01-4.26(m,22H),3.88-4.00(m,6H),3.77-3.81(m ,7H),3.49-3.76(m,45H),3.33-3.47(m,10H),2.56-2.62(m,2H),2.45-2.55(m,3H),2.21-2.38(m,7H), 2.14(s,12H),2.05-2.11(m,2H),2.02(s,12H),1.92-1.96(m,24H),1.47-1.68(m,4H),1.28-1.34(m,8H)

[0624] MS: m / z = 3022.36 (M+H) + .

[0625] Example 2 Preparation of siRNA

[0626] The siRNA of the present invention is prepared using the solid phase phosphoramidite method well known in the art. Specific methods can be found in, for example, PCT Publication Nos. WO2016081444 and WO2019105419, and are briefly described below.

[0627] 1. Preparation of siRNA without Ligand

[0628] 1.1 Synthesis of the positive sense chain (SS chain)

[0629] Using solid-phase phosphoramidite synthesis, a blank CPG solid support is used as the starting cycle, and nucleoside monomers are linked one by one in the 3'-5' direction according to the order of the positive strand nucleotides. Each linking step involves four steps: deprotection, coupling, capping, and oxidation or thiolation. The synthesis conditions for a 5μmol oligonucleotide are as follows:

[0630] Commercially available phosphoramidites with 2'-F, 2'-O-methyl, and other modifications were used. Nucleoside monomers were provided in 0.05 mol / L acetonitrile. The reaction conditions for each step were identical: 25°C, three deprotection cycles with 3% trichloroacetic acid in dichloromethane, two coupling reactions with 0.25 mol / L ETT in acetonitrile as the activator, and two capping reactions with 10% acetic anhydride in acetonitrile and pyridine / N-methylimidazole / acetonitrile (10:14:76, v / v / v). Oxidation reactions were performed twice with 0.05 mol / L iodine / tetrahydrofuran / pyridine / water (70 / 20 / 10, v / v / v), and two thiolation reactions with 0.2 mol / L PADS in acetonitrile / 3-methylpyridine (1 / 1, v / v).

[0631] 1.2 Synthesis of antisense strand (AS strand)

[0632] Using solid-phase phosphoramidite synthesis, a blank CPG solid support is used as the starting cycle. Nucleoside monomers are linked one by one in the 3'-5' direction according to the nucleotide arrangement of the antisense strand. Each ligation step involves four steps: deprotection, coupling, capping, and oxidation or thiolation. The synthesis conditions for a 5 μmol oligonucleotide of the antisense strand are the same as those for the sense strand.

[0633] 1.3 Oligonucleotide purification and annealing

[0634] 1.3.1 Ammonolysis

[0635] The synthesized solid phase carrier (sense chain or antisense chain) was added to a 5 mL centrifuge tube, 3% diethylamine / ammonia water (v / v) was added, and the reaction was carried out in a constant temperature water bath at 35°C for 16 hours (or in a constant temperature water bath at 55°C for 8 hours). After filtering, the solid phase carrier was washed three times with ethanol / water, each time with 1 mL. The filtrate was centrifuged and concentrated, and the crude product was purified.

[0636] 1.3.2 Purification

[0637] Purification and desalination methods are well known in the art. For example, a column packed with a strong anionic filler can be used, and elution and purification can be performed using a sodium chloride-sodium hydroxide system, with the product collected and stored in a tube. Desalination can also be performed using a gel-filled purification column, with pure water as the elution system.

[0638] 1.3.3 Annealing

[0639] According to Table 6, the sense chain (SS chain) and the antisense chain (AS chain) were mixed at a molar ratio (SS chain / AS chain = 1 / 1.05), heated in a water bath to 70-95° C. for 3-5 min, cooled naturally to room temperature, and the system was lyophilized to obtain the product.

[0640] Finally, the siRNAs shown in Table 6 were obtained.

[0641] 2. Preparation of siRNA with Sense Strand Linked to Ligand

[0642] 2.1 Ligand-CPG Carrier Connection

[0643] Ligation of compound E7 with CPG carrier

[0644] Compound E7 (53 mg, 0.018 mmol) and HBTU (13.3 mg, 0.035 mmol) were mixed and added to acetonitrile (5 mL) and shaken to dissolve. DIEA (9.0 mg, 0.07 mmol) and DMAP (2.1 mg, 0.018 mmol) were then added and shaken to dissolve until the solution became clear. ) was added to the reaction solution, and the reaction was shaken overnight at 20°C. Samples were taken and monitored for TLC, which indicated the reaction was complete. The developing solvent was DCM / methanol = 4:1, and the color was developed with phosphomolybdic acid. Filtered using a fritted funnel, the filter cake was washed with anhydrous acetonitrile (20 mL x 5), and the filter cake was filtered under reduced pressure using an oil pump for 6 h to obtain 530 mg of an off-white solid.

[0645] Place 530 mg of the condensed product in a 50 mL round-bottom flask. Add Cap C (DMAP / acetonitrile), Cap B (N-methylimidazole / pyridine / acetonitrile), and Cap A (acetic anhydride / acetonitrile) in that order. Shake overnight at room temperature. Filter, wash the filter cake with acetonitrile (20 mL x 4). Remove the filter cake and filter under reduced pressure with an oil pump for 8 hours to obtain 200 mg of an off-white solid, which was used for solid-phase synthesis.

[0646] 2.2 Synthesis of the positive sense chain (SS chain)

[0647] Using the solid-phase phosphoramidite synthesis method, using the DL0043 solid support prepared above as the starting cycle, nucleoside monomers were attached one by one in the 3'-5' direction according to the order of the positive strand nucleotides. Each ligation of a nucleoside monomer involved four steps: deprotection, coupling, capping, and oxidation or thiolation. The conditions for the synthesis of a 5 μmol oligonucleotide were as follows:

[0648] The nucleoside monomer was provided in a 0.05 mol / L acetonitrile solution. The reaction conditions for each step were the same, i.e., the temperature was 25°C, and deprotection was performed three times using a 3% trichloroacetic acid-dichloromethane solution. The coupling reaction was performed twice using a 0.25 mol / L ETT-acetonitrile solution as the activator. Capping was performed twice using 10% acetic anhydride-acetonitrile and pyridine / N-methylimidazole / acetonitrile (10:14:76, v / v / v). Oxidation was performed twice using 0.05 mol / L iodine / tetrahydrofuran / pyridine / water (70 / 20 / 10, v / v / v). Thiolysis was performed twice using 0.2 mol / L PADS in acetonitrile / 3-methylpyridine (1 / 1, v / v).

[0649] 2.3 Synthesis of antisense strand (AS strand)

[0650] Using solid-phase phosphoramidite synthesis, a blank CPG solid support is used as the starting cycle. Nucleoside monomers are linked one by one in the 3'-5' direction according to the nucleotide arrangement of the antisense strand. Each ligation step involves four steps: deprotection, coupling, capping, and oxidation or thiolation. The synthesis conditions for a 5 μmol oligonucleotide of the antisense strand are the same as those for the sense strand.

[0651] 2.4 Oligonucleotide Purification and Annealing

[0652] 2.4.1 Ammonolysis

[0653] The synthesized solid phase carrier (sense chain or antisense chain) was added to a 5 mL centrifuge tube, 3% diethylamine / ammonia water (v / v) was added, and the reaction was carried out in a constant temperature water bath at 35°C (or 55°C) for 16 hours (or 8 hours). After filtering, the solid phase carrier was washed three times with ethanol / water, each time with 1 mL. The filtrate was centrifuged and concentrated, and the crude product was purified.

[0654] 2.4.2 Purification

[0655] Purification and desalination methods are well known in the art. For example, a column packed with a strong anion filler can be used, and a sodium chloride-sodium hydroxide system can be used for elution and purification. The product can be collected and pipetted, and desalination can be performed using a gel-filled purification column, and the elution system can be pure water.

[0656] 2.4.3 Annealing

[0657] According to Table 7, the sense strand (SS strand) and the antisense strand (AS strand) were mixed at a molar ratio of SS strand / AS strand = 1 / 1.05. The mixture was heated in a water bath to 70-95°C for 3-5 minutes, cooled naturally to room temperature, and lyophilized to obtain the product. The siRNAs listed in Table 7 were obtained, with DR005677 used as a control.

[0658] Example 3 Activity screening of Huh7 cell line

[0659] Cell transfection

[0660] On the first day, Huh7 cells were digested, resuspended, and counted. The cell suspension was plated into a 96-well plate at 100 μL / well, with 1×10 4 cells / well, and transfection was performed 18 h later.

[0661] On the second day, 20 μM siRNA stock solution was diluted with Opti-MEM. 198 μL Opti-MEM was added to 2 μL siRNA stock solution. The final siRNA concentration was as shown below. Pipet and mix thoroughly and set aside.

[0662] The next day, dilute 0.9 μL of RNAiMAX (Thermo, 13778150) in 14.1 μL of Opti-MEM. Gently pipette to mix thoroughly, and let stand at room temperature for 5 minutes. Then, take 15 μL of the prepared RNAi-MAX mixture and 15 μL of the diluted siRNA and gently pipette to mix thoroughly, avoiding the introduction of bubbles. Let stand at room temperature for 10 minutes. Add 10 μL / well to a 96-well plate. Incubate in a 37°C, 5% CO2 incubator for 24 hours (no siRNA was added to the control group).

[0663] RNA extraction

[0664] Cell RNA was extracted using a nucleic acid extractor (Auto-pure96, Hangzhou Aosheng) according to the operating instructions of the high-throughput cell RNA extraction kit (Fanzhi Medical, FG0417-L).

[0665] RNA reverse transcription

[0666] Denaturation reaction mixture preparation reference PrimeScript TM II 1st Strand cDNA Synthesis Kit (Takara, 6210B), single-well preparation volume: Oligo dT Primer 1 μL, dNTP Mixture 1 μL, template RNA 12.5 μL, incubate at 65°C in a conventional PCR instrument for 5 minutes, then quickly cool on ice for 2 minutes.

[0667] Reverse transcription reaction solution preparation reference PrimeScript TM II 1st Strand cDNA Synthesis Kit (Takara, 6210B). Each well contains 4 μL of 5× PrimeScript II Buffer, 0.5 μL of RNase Inhibitor, and 1 μL of PrimeScript II RTase.

[0668] Slowly mix 14.5 μL of the denatured reaction solution with the reverse transcription reaction solution, incubate at 42°C for 45 minutes for reverse transcription using a conventional PCR instrument, incubate at 95°C for 5 minutes to inactivate the enzyme, and cool the reverse transcription product (cDNA) at 4°C.

[0669] After reverse transcription, 30 μL of distilled water free of DNase and RNase was added to the cDNA sample in each well.

[0670] Fluorescence quantitative PCR

[0671] ReferenceTaqMan TM Quantitative PCR (ABI, QuantStudio3) was performed using 20 μL of Fast Advanced Master Mix (ABI, 4444965). The reaction schedule was: (50°C, 2 minutes) × 1 cycle; (95°C, 20 seconds) × 1 cycle; (95°C, 1 second; 60°C, 24 seconds) × 40 cycles.

[0672] Table 8. Primer information

[0673] Statistics

[0674] Calculation 2 -△△Ct The values ​​were converted into percentages to obtain the residual inhibition rate; ΔΔCt=[(Ct experimental group target gene-Ct experimental group internal reference)-(Ct control group target gene-Ct control group internal reference)].

[0675] The target gene was hAGT, and the internal reference was hACTB.

[0676] The final concentration of siRNA was 10 nM for siRNA compound cell line activity screening. The experimental screening results are shown in Table 9.

[0677] Table 9. Huh7 cell line activity screening results

[0678] Example 4 Activity screening of primary human hepatocytes (PHH cells)

[0679] Cell transfection

[0680] Take 1.4 mL of rat tail collagen solution (Sigma, C3867), add it to 40.6 mL of distilled water without DNase and RNase, mix well, add 40 μL to each well of a 96-well culture plate, coat overnight at 4°C, and remove the coating solution the next day.

[0681] On the second day, before use, the coated cell plate was rinsed with DPBS and then the DPBS was removed. PHH cells (Shanghai Xuanyi, product number QYLF-HPMC) were revived at 37°C, added to the recovery medium, centrifuged, resuspended and counted. PHH cells were plated in a 96-well plate at 90 μL / well, 2×10 4 cells / well; complete culture medium was replaced after 4 hours, and transfection was performed after 18 hours.

[0682] On the third day, 20 μM siRNA stock solution was diluted with Opti-MEM. 198 μL Opti-MEM was added to 2 μL siRNA stock solution and mixed by pipetting. This was used as the first concentration point and gradient dilution was performed according to actual experimental needs.

[0683] On the third day, dilute 0.9 μL of RNAiMAX (Thermo, 13778150) with 14.1 μL of Opti-MEM. Gently pipette to mix thoroughly, and let stand at room temperature for 5 minutes. Then, take 15 μL of the prepared RNAi-MAX mixture and 15 μL of the diluted compound and gently pipette to mix thoroughly, avoiding the introduction of bubbles. Let stand at room temperature for 10 minutes. Add 10 μL / well to a 96-well plate. Incubate in a 37°C, 5% CO2 incubator for 24 hours before RNA extraction.

[0684] RNA extraction

[0685] Cell RNA was extracted using a nucleic acid extractor (Hangzhou Aosheng, Auto-pure96) according to the operating procedures of a high-throughput cell RNA extraction kit (Fanzhi Medical, FG0412).

[0686] RNA reverse transcription

[0687] For preparation of denaturation reaction mixture, refer to PrimeScript TM II 1st Strand cDNA Synthesis Kit (Takara, 6210B). Each well contains 1 μL of Oligo dT Primer, 1 μL of dNTP Mixture, and 12.5 μL of template RNA. Incubate at 65°C for 5 minutes in a conventional PCR instrument to perform the denaturation reaction. Rapidly cool the mixture on ice for 2 minutes.

[0688] Preparation of reverse transcription reaction solution, refer to PrimeScript TMII 1st Strand cDNA Synthesis Kit (Takara, 6210B). Each well contains 4 μL of 5× PrimeScript II Buffer, 0.5 μL of RNase Inhibitor, and 1 μL of PrimeScript II RTase.

[0689] 14.5 μL of the denatured reaction solution was slowly mixed with the reverse transcription reaction solution, incubated at 42° C. for 45 min in a conventional PCR instrument for reverse transcription, incubated at 95° C. for 5 min to inactivate the enzyme, and the reverse transcription product (cDNA) was cooled at 4° C.

[0690] After reverse transcription, 30 μL of DNase- and RNase-free distilled water was added to the cDNA sample in each well.

[0691] Fluorescence quantitative PCR

[0692] ReferenceTaqMan TM Fast Advanced Master Mix (ABI, 4444965) was used to perform fluorescent quantitative PCR reactions (ABI, QuantStudio3) in 20 μL of the system. The reaction program was: (50°C, 2 min) × 1 cycle; (95°C, 20 s) × 1 cycle; (95°C, 1 s; 60°C, 24 s) × 40 cycles.

[0693] Table 10 Primer information

[0694] Statistics

[0695] Calculation 2 -△△Ct The values ​​were converted into percentages to obtain the residual inhibition rate.

[0696] △△Ct=[(target gene of Ct experimental group-internal reference of Ct experimental group)-(target gene of Ct control group-internal reference of Ct control group)].

[0697] The starting concentration of siRNA was 10 nM, and 5-fold gradient dilution was performed to obtain 5 concentration points (10 nM, 1 nM, 0.1 nM, 0.01 nM, 0.001 nM). The activity of siRNA in human primary liver cells was screened. The screening results are shown in Table 10, where columns 2-6 are the residual inhibition rates and column 7 is the IC50 value.

[0698] Table 11 Results of screening human primary hepatocytes using 5 concentrations of siRNA

[0699] Example 5 Screening of off-target activity of psiCHECK2 GSSM-5 Hits

[0700] Plasmid preparation

[0701] The corresponding antisense off-target plasmid was designed according to the siRNA sequence, and the psiCHECK2 GSSM-5Hits recombinant plasmid was prepared by Sangon Biotech (Shanghai) Co., Ltd. and diluted to 1000 ng / μL for later use.

[0702] Cell transfection

[0703] In each well of a 96-well plate, 100 μL of HEK293A cell suspension (Nanjing Kebai, catalog number CBP60436) was used to plate the cells. 8×10 3 cells / well.

[0704] On the second day, the complete culture medium in the wells was first aspirated and replaced with 80 μL / well of Opti-MEM medium, and the cells were starved for about 1.5 h.

[0705] siRNA preparation: Dilute siRNA 3-fold starting from a final concentration of 40 nM, for a total of 11 concentration points (10 nM, 3.3333 nM, 1.1111 nM, 0.37037 nM, 0.12346 nM, 0.04115 nM, 0.01372 nM, 0.00457 nM, 0.00152 nM, 0.00051 nM, 0.00017 nM).

[0706] Preparation of plasmid mixture: The preparation volume for a single well is 0.01 μL / well of plasmid and 8.99 μL / well of Opti-MEM.

[0707] Preparation of Lipo mixture: Lipo 2000 0.2 μL and Opti-MEM 9.8 μL were added to each well to dilute Lipo 2000 (Lipofectamine TM 2000 transfection reagent, Thermo, 11668019) to obtain the Lipo mixture, and let it stand at room temperature for 5 minutes.

[0708] Aliquot 22 μL of the prepared Lipo mixture, 2.2 μL of siRNA, and 19.8 μL of the plasmid mixture into corresponding wells, designated well A. Mix thoroughly by pipetting and incubate at room temperature for 20 minutes before co-transfection. Add 20 μL of well A mixture to each well of cells, adding 80 μL of Opti-MEM to the original volume, for a final volume of 100 μL per well. After incubation at 37°C in a 5% CO2 incubator for 4 hours, add 100 μL of DMEM medium supplemented with 20% fetal bovine serum to each well. Incubate at 37°C in a 5% CO2 incubator for 24 hours before testing.

[0709] Result detection

[0710] Before the experiment, mix ( Luciferase Assay System, Promega, E2940) was reconstituted and after equilibration to room temperature, DMEM was added to each tube at a ratio of 1:1 to prepare substrate I for immediate use. Stop& Buffer was reconstituted and then equilibrated to room temperature. Stop& Prepare substrate II at a 100:1 ratio and use immediately. Use a vacuum pump to remove the existing culture medium from the 96-well culture plate. Add 150 μL of substrate I to each well and incubate on a shaker at room temperature for 10 minutes. Transfer 120 μL of substrate I to a 96-well microplate reader and read the Firefly chemiluminescence value on a microplate reader (Tecan, Infinite 200). Add 60 μL of substrate II to each well and incubate on a shaker at room temperature for 10 minutes. Read the Renilla chemiluminescence value on a microplate reader.

[0711] Data analysis and processing

[0712] Fluorescence activity was measured by a microplate reader. The collected Renilla signal was normalized by the Firefly signal standard. The inhibitory effect of siRNA was calculated by comparing it with the untreated result (residual inhibitory activity). The calculation process is as follows:

[0713] Normalized Ren / Fir ratio: Ratio = Renilla (Renilla luciferase) / Firefly (Firefly luciferase).

[0714] Residual inhibition rate = (RatiosiRNA / Ratiocontrol)*100%, taking the average of two replicate wells: Ratiocontrol is the Ratio value of the control well (without siRNA) (taking the average of two replicate wells).

[0715] Graphing: Graphpad Prism

[0716] Half maximal inhibitory concentration (IC50): In this experiment, Top and Bottom plots were used. The IC50 value was calculated using the formula Y = Bottom + (Top - Bottom) / (1 + 10^((LogIC50 - X) * HillSlope)), where Y = 50 and X = log(concentration).

[0717] The results of the psiCHECK2 GSSM-5Hits off-target activity screening of siRNA are shown in Table 12, where columns 2-12 are the residual inhibition rates and column 13 is the IC50 value.

[0718] Table 12 psiCHECK2 GSSM-5Hits off-target activity screening results

[0719] Example 6 Activity Detection of AAV Humanized Mouse Model

[0720] AAV8 virus carrying the human AGT gene fragment (purchased from Heyuan Bio) was injected into mice via the tail vein at a viral dose of 1 x 10 11 vg. The day of virus injection was designated as day -14, and mouse serum was collected on day -1. AGT protein was detected by ELISA (detection kit purchased from Abcam, catalog number ab267592) as the baseline. The mice were divided into groups for administration, with 3 mice in each group. On day 0, siRNA drugs were administered via tail vein injection at a dose of 1 mg / kg. Serum was collected on days 7, 14, 28, and 42 (D7, D14, D28, and D42) after administration, and AGT protein levels were detected using the above-mentioned kit. The residual rate was calculated with the baseline level as 100%.

[0721] Table 13 Activity evaluation results in AAV mice

[0722] Example 7 In vivo activity evaluation in transgenic mouse models

[0723] After the adaptation period, male C57BL / 6J transgenic mice were bled on the 4th day before administration (D-4). Serum samples were collected from each mouse through the orbital vein, and serum samples were collected after centrifugation. The human AGT protein level in each mouse serum was detected by ELISA as the experimental baseline, and group administration (4 mice per group) was performed according to the baseline level. On the day of administration (D0), each group of mice was given normal saline or siRNA of the present invention by subcutaneous injection, with a dosage of 1 or 3 mg / kg (mpk) and a dosing volume of 5 ml / kg. Mouse serum was collected on the 7th, 14th, 21st, 28th, 35th, 42nd, 56th and 70th day after administration, and the human AGT protein level was measured by ELISA (detection kit purchased from Abcam, article number ab267592). The siRNA knockdown efficiency was calculated by comparing the human AGT protein level in the serum of each mouse before and after administration. The experimental results are shown in Table 14.

[0724] Table 14 Activity evaluation results of siRNA compounds in human AGT transgenic mice

[0725] ND means not detected

[0726] Example 8 In vivo efficacy evaluation of siRNA in diet-induced hypertensive cynomolgus monkeys

[0727] Sixteen male hypertensive cynomolgus monkeys were divided into four groups based on serum AGT levels, body weight, and blood pressure. They were given a single subcutaneous injection of physiological saline (i.e., vehicle group) or the siRNA of the present invention at a dose of 10 mg / kg in a volume of 1 ml / kg. Serum was collected on day 6 before administration (D-6), on the day of administration (D0), and on days 3, 7, 14, 21, 28, 35, 42, 55, 70, 77, 84, 91, 98, and 105 after administration. Serum AGT protein levels were measured by ELISA (IBL-Japan, Cat. No. 27412). Blood pressure was measured weekly at the left wrist or tail base using a high-definition oscilloscope (HDO). The siRNA knockdown efficiency was calculated by comparing the AGT protein levels in the serum of each monkey on the day of administration and at various time points after administration. The reduction in serum AGT protein, systolic blood pressure (SBP), diastolic blood pressure (DBP) and mean arterial pressure (MAP) by each group of compounds is shown in Figures 1, 2, 3 and 4.

[0728] The results showed that all compounds had a high inhibition rate on serum AGT protein (maximum inhibition rate >98%). At 105 days after administration, DR009219 and DR009221 still had inhibition rates exceeding 90%. After 14 days, all compounds significantly reduced systolic blood pressure, with the maximum reduction ranging from 40-50 mmHg. At 105 days after administration, the systolic blood pressure of monkeys in each treatment group remained significantly lower than that of the control group. All compounds significantly reduced diastolic blood pressure, with the maximum reduction ranging from 20-30 mmHg. At 105 days after administration, the diastolic blood pressure of monkeys in each treatment group remained significantly lower than that of the control group.

Claims

1. A double-stranded RNA (dsRNA) for inhibiting the expression of angiotensinogen (AGT) in a cell, the dsRNA comprising a sense strand and an antisense strand forming a double-stranded region, wherein the sense strand and the antisense strand are each independently 15-30 nucleotides in length, and the antisense strand comprises a nucleotide sequence of at least 15 consecutive nucleotides of the nucleotide sequence shown in any one of SEQ ID NOs: 21-40.

2. The dsRNA of claim 1, wherein the sense strand comprises a nucleotide sequence of at least 15 consecutive nucleotides of the nucleotide sequence shown in any one of SEQ ID NOs: 1-20.

3. The dsRNA of claim 1 or 2, wherein the dsRNA is siRNA.

4. The dsRNA according to any one of claims 1 to 3, wherein the length of the double-stranded region is 15-25 nucleotide pairs, preferably 16-23 nucleotide pairs, more preferably 18-20 nucleotide pairs.

5. The dsRNA of any one of claims 1 to 4, wherein the antisense strand comprises a nucleotide sequence of at least 16 consecutive nucleotides, a nucleotide sequence of at least 17 consecutive nucleotides, a nucleotide sequence of at least 18 consecutive nucleotides, a nucleotide sequence of at least 19 consecutive nucleotides, or a nucleotide sequence of at least 20 consecutive nucleotides of the nucleotide sequence shown in any one of SEQ ID NOs: 21 to 40, preferably the antisense strand comprises the nucleotide sequence shown in any one of SEQ ID NOs: 21 to 40.

6. The dsRNA of any one of claims 1 to 5, wherein the sense strand comprises a nucleotide sequence of at least 16 consecutive nucleotides, a nucleotide sequence of at least 17 consecutive nucleotides, or a nucleotide sequence of at least 18 consecutive nucleotides of the nucleotide sequence shown in any one of SEQ ID NOs: 1 to 20, preferably the sense strand comprises the nucleotide sequence shown in any one of SEQ ID NOs: 1 to 20.

7. The dsRNA of any one of claims 1 to 6, wherein the siRNA comprises any one of the following paired sense strand sequence and antisense strand sequence: (1) Sense strand: SEQ ID NO: 1, antisense strand: SEQ ID NO: 21; (2) Sense strand: SEQ ID NO: 2, antisense strand: SEQ ID NO: 22; (3) Sense strand: SEQ ID NO: 3, antisense strand: SEQ ID NO: 23; (4) Sense strand: SEQ ID NO: 4, antisense strand: SEQ ID NO: 24; (5) Sense strand: SEQ ID NO: 5, antisense strand: SEQ ID NO: 25; (6) Sense strand: SEQ ID NO: 6, antisense strand: SEQ ID NO: 26; (7) Sense strand: SEQ ID NO: 7, antisense strand: SEQ ID NO: 27; (8) Sense strand: SEQ ID NO: 8, antisense strand: SEQ ID NO: 28; (9) Sense strand: SEQ ID NO: 9, antisense strand: SEQ ID NO: 29; (10) Sense strand: SEQ ID NO: 10, antisense strand: SEQ ID NO: 30; (11) Sense strand: SEQ ID NO: 11, antisense strand: SEQ ID NO: 31; (12) Sense strand: SEQ ID NO: 12, antisense strand: SEQ ID NO: 32; (13) Sense strand: SEQ ID NO: 13, antisense strand: SEQ ID NO: 33; (14) Sense strand: SEQ ID NO: 14, antisense strand: SEQ ID NO: 34; (15) Sense strand: SEQ ID NO: 15, antisense strand: SEQ ID NO: 35; (16) Sense strand: SEQ ID NO: 16, antisense strand: SEQ ID NO: 36; (17) Sense strand: SEQ ID NO: 17, antisense strand: SEQ ID NO: 37; (18) Sense strand: SEQ ID NO: 18, antisense strand: SEQ ID NO: 38; (19) sense strand: SEQ ID NO: 19, antisense strand: SEQ ID NO: 39; and (20) Sense strand: SEQ ID NO: 20, antisense strand: SEQ ID NO:

40.

8. The dsRNA of any one of claims 1 to 7, wherein substantially all of the nucleotides of the sense strand and substantially all of the nucleotides of the antisense strand are modified nucleotides, or all of the nucleotides of the sense strand and all of the nucleotides of the antisense strand are modified nucleotides.

9. The dsRNA of any one of claims 1 to 8, wherein the sense strand and the antisense strand each independently comprise one or more nucleotide modifications selected from the group consisting of a 2'-O-methyl modification, a 2'-fluoro modification, an SCP modification, an ethylene glycol modification, and a modification of a phosphorothioate internucleotide linkage.

10. The dsRNA of any one of claims 1-9, wherein the antisense strand has a length of 21 nucleotides and has (i) (counting from the 5' end) 2'-O-methyl modified nucleotides at positions 1, 3, 5, 9, 11, 13, 15, 17, 19 and 21, and 2'-fluoro modified nucleotides at positions 2, 4, 6, 8, 10, 12, 14, 16, 18 and 20; and / or (ii) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, between nucleotide positions 2 and 3, between nucleotide positions 19 and 20, and between nucleotide positions 20 and 21 (counting from the 5' end).

11. The dsRNA of any one of claims 1-9, wherein the antisense strand has a length of 21 nucleotides and has (i) 2'-O-methyl modified nucleotides at positions 3, 4, 6, 8, 9, 10, 11, 13, 15, 16, 17, 18, 19, 20 and 21 (counting from the 5' end); (ii) a 2'-fluoro-modified nucleotide at position 14 (counting from the 5' end); (iii) 2'-deoxy modifications at positions 2, 5, 7 and 12 (counting from the 5' end); (iv) a SCP modification at position 1 (counting from the 5' end); and / or (v) Phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, between nucleotide positions 2 and 3, between nucleotide positions 19 and 20, and between nucleotide positions 20 and 21 (counting from the 5' end).

12. The dsRNA of any one of claims 1-9, wherein the antisense strand has a length of 21 nucleotides and has (i) 2'-O-methyl modified nucleotides at positions 3, 5, 9, 11, 13, 15, 17, 19, 20 and 21 (counting from the 5' end); (ii) 2'-fluoro-modified nucleotides at positions 2, 4, 6, 8, 10, 12, 14, 16 and 18 (counting from the 5' end); (iii) GNA modification at position 7 (counting from the 5' end); (iv) a SCP modification at position 1 (counting from the 5' end); and / or (v) Phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, between nucleotide positions 2 and 3, between nucleotide positions 19 and 20, and between nucleotide positions 20 and 21 (counting from the 5' end).

13. The dsRNA of any one of claims 1-9, wherein the sense strand has a length of 19 nucleotides and has: (i) (counting from the 5' end) 2'-O-methyl modified nucleotides at positions 1 to 6, 10 to 19, and 2'-fluoro modified nucleotides at positions 7-9; and / or (ii) Phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, between nucleotide positions 2 and 3, and between nucleotide positions 18 and 19 (counting from the 5' end).

14. The dsRNA of any one of claims 8-12, wherein the antisense strand comprises a sequence selected from any one of SEQ ID NOs: 81-105.

15. The dsRNA of any one of claims 8-9, 13-14, wherein the sense strand comprises a sequence selected from any one of SEQ ID NOs: 41-59.

16. The dsRNA of claim 15, wherein the dsRNA comprises any one pair of paired sense strand sequence and antisense strand sequence selected from the group consisting of: Sense strand: SEQ ID NO:41, antisense strand: SEQ ID NO:81; Sense strand: SEQ ID NO: 42, antisense strand: SEQ ID NO: 82; Sense strand: SEQ ID NO: 43, antisense strand: SEQ ID NO: 83; Sense strand: SEQ ID NO: 44, antisense strand: SEQ ID NO: 84; Sense strand: SEQ ID NO: 45, antisense strand: SEQ ID NO: 85; Sense strand: SEQ ID NO: 46, antisense strand: SEQ ID NO: 86; Sense strand: SEQ ID NO: 47, antisense strand: SEQ ID NO: 87; Sense strand: SEQ ID NO: 48, antisense strand: SEQ ID NO: 88; Sense strand: SEQ ID NO: 49, antisense strand: SEQ ID NO: 89; Sense strand: SEQ ID NO: 50, antisense strand: SEQ ID NO: 90; Sense strand: SEQ ID NO: 51, antisense strand: SEQ ID NO: 91; Sense strand: SEQ ID NO: 52, antisense strand: SEQ ID NO: 92; Sense strand: SEQ ID NO: 53, antisense strand: SEQ ID NO: 93; Sense strand: SEQ ID NO: 54, antisense strand: SEQ ID NO: 94; Sense strand: SEQ ID NO: 55, antisense strand: SEQ ID NO: 95; Sense strand: SEQ ID NO: 56, antisense strand: SEQ ID NO: 96; Sense strand: SEQ ID NO: 57, antisense strand: SEQ ID NO: 97; Sense strand: SEQ ID NO: 58, antisense strand: SEQ ID NO: 98; and Sense strand: SEQ ID NO:59, antisense strand: SEQ ID NO:

99.

17. The dsRNA of any one of claims 8-9, 13-14, wherein the sense strand comprises a sequence selected from any one of SEQ ID NOs: 113-131.

18. The dsRNA of claim 17, wherein the dsRNA comprises any one pair of paired sense strand sequence and antisense strand sequence selected from the group consisting of: Sense strand: SEQ ID NO: 113, antisense strand: SEQ ID NO: 81; Sense strand: SEQ ID NO: 114, antisense strand: SEQ ID NO: 82; Sense strand: SEQ ID NO: 115, antisense strand: SEQ ID NO: 83; Sense strand: SEQ ID NO: 116, antisense strand: SEQ ID NO: 84; Sense strand: SEQ ID NO: 117, antisense strand: SEQ ID NO: 85; Sense strand: SEQ ID NO: 118, antisense strand: SEQ ID NO: 86; Sense strand: SEQ ID NO: 119, antisense strand: SEQ ID NO: 87; Sense strand: SEQ ID NO: 120, antisense strand: SEQ ID NO: 88; Sense strand: SEQ ID NO: 121, antisense strand: SEQ ID NO: 89; Sense strand: SEQ ID NO: 122, antisense strand: SEQ ID NO: 90; Sense strand: SEQ ID NO: 123, antisense strand: SEQ ID NO: 91; Sense strand: SEQ ID NO: 124, antisense strand: SEQ ID NO: 92; Sense strand: SEQ ID NO: 125, antisense strand: SEQ ID NO: 93; Sense strand: SEQ ID NO: 126, antisense strand: SEQ ID NO: 94; Sense strand: SEQ ID NO: 127, antisense strand: SEQ ID NO: 95; Sense strand: SEQ ID NO: 128, antisense strand: SEQ ID NO: 96; Sense strand: SEQ ID NO: 129, antisense strand: SEQ ID NO: 97; Sense strand: SEQ ID NO: 130, antisense strand: SEQ ID NO: 98; and Sense strand: SEQ ID NO: 131, antisense strand: SEQ ID NO:

99.

19. The dsRNA of any one of claims 1 to 18, wherein the dsRNA is further conjugated to a ligand moiety comprising N-acetylgalactosamine, preferably the 3' end of the sense strand is conjugated to the ligand moiety.

20. The dsRNA of any one of claims 19, wherein the ligand has the following structure: in indicates the position linked to the sense strand of the dsRNA via a phosphate group or a phosphorothioate group.

21. The dsRNA of claim 19 or 20, wherein the sense strand comprises a sequence selected from any one of SEQ ID NOs: 60-79.

22. The dsRNA of claim 21, comprising any pair of sense strand sequence and antisense strand sequence selected from the group consisting of: Sense strand: SEQ ID NO: 60, antisense strand: SEQ ID NO: 81; Sense strand: SEQ ID NO: 61, antisense strand: SEQ ID NO: 82; Sense strand: SEQ ID NO: 62, antisense strand: SEQ ID NO: 83; Sense strand: SEQ ID NO: 63, antisense strand: SEQ ID NO: 84; Sense strand: SEQ ID NO: 64, antisense strand: SEQ ID NO: 85; Sense strand: SEQ ID NO: 65, antisense strand: SEQ ID NO: 86; Sense strand: SEQ ID NO: 66, antisense strand: SEQ ID NO: 87; Sense strand: SEQ ID NO: 67, antisense strand: SEQ ID NO: 88; Sense strand: SEQ ID NO: 68, antisense strand: SEQ ID NO: 89; Sense strand: SEQ ID NO: 69, antisense strand: SEQ ID NO: 90; Sense strand: SEQ ID NO: 70, antisense strand: SEQ ID NO: 91; Sense strand: SEQ ID NO: 71, antisense strand: SEQ ID NO: 92; Sense strand: SEQ ID NO: 72, antisense strand: SEQ ID NO: 93; Sense strand: SEQ ID NO: 73, antisense strand: SEQ ID NO: 94; Sense strand: SEQ ID NO: 74, antisense strand: SEQ ID NO: 95; Sense strand: SEQ ID NO: 75, antisense strand: SEQ ID NO: 96; Sense strand: SEQ ID NO: 76, antisense strand: SEQ ID NO: 97; Sense strand: SEQ ID NO: 77, antisense strand: SEQ ID NO: 98; Sense strand: SEQ ID NO: 78, antisense strand: SEQ ID NO: 99; Sense strand: SEQ ID NO: 72, antisense strand: SEQ ID NO: 100; Sense strand: SEQ ID NO: 72, antisense strand: SEQ ID NO: 101; Sense strand: SEQ ID NO: 72, antisense strand: SEQ ID NO: 102; Sense strand: SEQ ID NO: 72, antisense strand: SEQ ID NO: 103; Sense strand: SEQ ID NO: 79, antisense strand: SEQ ID NO: 104; and Sense strand: SEQ ID NO:79, antisense strand: SEQ ID NO:

105.

23. A vector comprising a nucleotide sequence encoding the dsRNA of any one of claims 1-22.

24. A cell comprising the dsRNA of any one of claims 1 to 22 or the vector of claim 23.

25. A pharmaceutical composition comprising the dsRNA of any one of claims 1 to 22, the vector of claim 23, or the cell of claim 24, and optionally a pharmaceutically acceptable carrier or excipient.

26. A kit comprising the dsRNA of any one of claims 1-22, the vector of claim 23, or the cell of claim 24.

27. A method for treating a disease or condition that would benefit from reduced expression of angiotensinogen (AGT) in a subject, the method comprising the step of administering to the subject a dsRNA according to any one of claims 1 to 22, a vector according to claim 23, a cell according to claim 24, or a pharmaceutical composition according to claim 25.

28. A method of preventing at least one symptom in a subject suffering from a disease or condition that would benefit from reduced expression of angiotensinogen (AGT), the method comprising the step of administering to the subject a dsRNA according to any one of claims 1 to 22, a vector according to claim 23, a cell according to claim 24, or a pharmaceutical composition according to claim 25.

29. The method of claim 27 or 28, wherein the disease or condition that would benefit from a reduction in angiotensinogen (AGT) expression is an AGT-mediated or AGT-related disease.

30. The method of claim 29, wherein the AGT-mediated or AGT-related disease is selected from the group consisting of: hypertension, ocular hypertension, glaucoma, hypertensive heart disease, hypertensive nephropathy, atherosclerosis, arteriosclerosis, vasculopathy, diabetic nephropathy, diabetic retinopathy, chronic heart failure, cardiomyopathy, diabetic cardiomyopathy, glomerulosclerosis, aortic coarctation, aortic aneurysm, ventricular fibrosis, heart failure, myocardial infarction, angina pectoris, stroke, nephropathy, renal failure, systemic sclerosis, intrauterine growth restriction (IUGR), fetal growth restriction, obesity, hepatic steatosis / fatty liver, non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD); glucose intolerance, type 2 diabetes (non-insulin-dependent diabetes mellitus) and metabolic syndrome.

31. The method of claim 30, wherein the hypertension is selected from the group consisting of borderline hypertension, essential hypertension, secondary hypertension, isolated systolic or diastolic hypertension, pregnancy-related hypertension, diabetic hypertension, resistant hypertension, refractory hypertension, paroxysmal hypertension, renovascular hypertension, Goldblatt hypertension, pulmonary hypertension, portal hypertension, systemic venous hypertension, systolic hypertension, and unstable hypertension.

32. A method of reducing the level of angiotensinogen (AGT) in a subject, the method comprising the step of administering to the subject the dsRNA of any one of claims 1-22, the vector of claim 23, the cell of claim 24, or the pharmaceutical composition of claim 25.

33. The method of any one of claims 27-32, wherein the dsRNA, vector, cell or pharmaceutical composition is administered subcutaneously, topically or intravenously.

34. The method of any one of claims 27-33, wherein the subject is a human.

Citation Information

Patent Citations

  • Carbohydrate conjugates as delivery agents for oligonucleotides

    WO2009073809A2

  • Targeting lipids

    WO2009082607A2

  • Modified nucleosides and oligomeric compounds prepared therefrom

    WO2011139702A2

  • Oligomer-conjugate complexes and their use

    WO2013033230A1

  • Organic compositions to treat APOC3-related diseases

    WO2016011123A1